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Burkholderia pseudomallei and Burkholderia mallei cause the diseases melioidosis and 
glanders, respectively. These diseases are endemic mainly in southeastern Asia and 
northern Australia, but they also pose a bioterrorism threat in the developed world. These 
diseases have high mortality, partially due to the lack of vaccines and rapid, accurate 
diagnostic assays. The work discussed here represents a part of a larger project to develop 
a dependable diagnostic assay for use in both developing endemic areas and the 
developed world, as well as a subunit vaccine to protect against disease. In this study, 
several proteins from B. pseudomallei, B. mallei, and the closely related but less virulent 
B. thailandensis have been cloned, expressed and purified in order to develop highly 
sensitive and specific diagnostic reagents for the detection of B. pseudomallei and B. 
mallei in infected patient samples. Protein targets expressed in this study were also used 
in subunit vaccine development for melioidosis and glanders.  
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Chapter 1: Introduction 
 
SECTION 1.1 BURKHOLDERIA SPECIES STUDIED 
 
Section 1.1a Genus Burkholderia 
 The genus Burkholderia consists of more than 40 species of Gram-negative, non 
spore-forming, oxidase positive bacteria. With the exception of Burkholderia mallei, they 
are all motile soil saprophytes (Vial et al. 2007) The genus is diverse, containing animal 
and plant pathogens as well as non-infectious organisms. For this study, the focus is on 
the major animal pathogens Burkholderia pseudomallei and B. mallei, with Burkholderia 
thailandensis being used as a model organism to develop methods for use on the above 
pathogenic species. 
Section 1.1b Burkholderia pseudomallei 
 B. pseudomallei  is a saprophytic Gram-negative bacillus that is found  in soil and 
surface water between latitudes 20 ˚N and 20 ˚S (reviewed in Cheng and Currie 2005). B. 
pseudomallei causes the often fatal disease melioidosis in humans, and can also cause 
lethal infections in several other species including large primates, birds, rodents, 
ungulates, and even sea mammals (reviewed in Cheng and Currie 2005). Melioidosis is 
primarily endemic in Southeast Asia and Northern Australia, but has also been found in 
the Middle East, China and South America (reviewed in Galyov et al. 2010). B. 




of all rice paddies (White 2003). The Centers for Disease Control (CDC) has classified B. 
pseudomallei as a biosafety level 3 agent and category B biothreat agent, because it could 
be easily disseminated, results in high mortality rates, and would require special action 
for public health preparedness (www.bt.cdc.gov/agent/agentlist-category.asp, (Dance 
2002). It has been investigated for potential bioweapon use by both the former USSR and 
the United States, and while B. pseudomallei has not been weaponized in the past, it has 
the potential to be an extremely lethal bioweapon  (Peacock et al. 2012). B. pseudomallei 
does not form spores, but it does have a polysaccharide capsule which produces a slime 
that makes it resistant to external factors including many antibiotics (White 2003). The 
capsule is a major virulence factor: mutants that have lost capsule production are greatly 
attenuated in virulence (Atkins et al. 2002). The bacterium needs water to survive 
environmentally, and does not tolerate cold or high or low pH conditions (Tong et al. 
1996). B. pseudomallei is motile by means of a polar tuft of 2-4 flagella. The flagella are 
a major antigenic component during infection, and they may be involved in attachment to 
the host cells (reviewed in Dance 2005). Other virulence factors of B. pseudomallei 
include lipopolysaccharide (LPS), capsule, quorum sensing molecules, and the Types III 
and VI Secretion System components (reviewed by Galyov et al. 2010 and references 
therein).  
B. pseudomallei strain K96243 was the first strain to be fully sequenced and its 
genome consists of two circular chromosomes (Holden et al. 2004). Chromosome one is 




core functions of the bacteria including amino acid metabolism and protein biosynthesis. 
Chromosome two is 3.17 Mb and encodes 2,395 coding sequences, a higher proportion of 
which code for accessory functions such as osmotic protection and iron acquisition 
(Holden et al. 2004). In addition, B. pseudomallei has many insertion sequences, 
transposable islands, and horizontally-acquired genomic islands (Woods 2002; Holden et 
al. 2004). Presently, there are 4 strains that have been completely sequenced, B. 
pseudomallei 1106b, 1710b, 668 and K96243, and several more have been partially 
sequenced  (ncbi.nlm.nih.gov/genome/genomes/476?subset=).  
Bp82, an avirulent mutant of B. pseudomallei strain 1026b (Brett et al. 1997), has 
been recently generated for research in biosafety level 2 settings (Propst et al. 2010). This 
strain is a !purM mutant, and is avirulent even at high doses. The purM gene encodes 
phosphoribosylformylglycinamide cycloligase, an enzyme upstream from the adenine 
and thiamine de novo synthesis pathway in the bacterium (Holden et al. 2004). The 
!purM mutant Bp82 has been engineered with a deletion that removes residues 95-132, 
leaving a markerless space and predicted expression of a truncated and nonfunctioning, 
99 residue protein (Propst et al. 2010). As a result, the mutant is an adenine auxotroph, 
however, repair of the mutation to the purM gene restores full virulence to the organism 
(Propst et al. 2010). Purine biosynthesis mutants have also been successfully generated 
for attenuation of other pathogens including: Francisella tularensis (Pechous et al. 2008), 
Brucella abortus (Alcantara et al. 2004), Shigella flexneri (Cersini et al. 2003), 




et al. 2002). 
 
Section 1.1c Burkholderia mallei  
B. mallei is a Gram-negative obligate intracellular pathogen that is the causative 
agent of glanders, a disease that is endemic in domestic animals in Asia, Africa, the 
Middle East, and South America (Elschner et al. 2011). Its natural reservoir is solipeds 
(e.g. horses and mules), where it causes a chronic form of the disease glanders, but the 
organism can also infect humans who are in close contact with infected animals. In 
animals other than horses and in humans the bacillus causes an acute form of glanders 
(Whitlock et al. 2007). B. mallei cannot persist in the environment outside of its natural 
host (Galyov et al. 2010). 
The CDC has classified B. mallei as a biosafety level 3 agent and category B 
biothreat agent, because it could be easily disseminated, results in high mortality rates, 
and would require special action for public health preparedness 
(www.bt.cdc.gov/agent/agentlist-category.asp, (Dance 2002). B. mallei has been used 
against horses in biowarfare throughout history, including the American Civil War, 
World Wars I and II, and in the Russian invasion of Afghanistan between 1979-1988. 
Glanders was believed to have been spread deliberately by German agents to infect large 
numbers of Russian horses and mules on the Eastern Front. B. mallei has also been used 
against prisoners of war by the Japanese in WWII (Lehavi et al. 2002; Rotz et al. 2002; 




 B. mallei does not form spores, but it does have a polysaccharide capsule which 
produces a slime that makes it resistant to external factors including many antibiotics 
(DeShazer et al. 2001). The capsule is a major virulence factor: mutants that have lost 
capsule production are avirulent in hamsters, mice and horses (DeShazer et al. 2001; 
Lopez et al. 2003). B. mallei is the only member of the genus Burkholderia that is non-
motile due to being non-flagellated. This is because of three major mutations in the 
flagellar synthesis pathway. There is a frameshift mutation in a methyl-accepting 
chemotaxis gene, a 65-kb sequence inserted into the fliP gene, which is essential for 
flagellum biosynthesis, and a second frameshift mutation in the motB gene, which codes 
for the flagellar motor protein (Nierman et al. 2004). Major virulence factors of B. mallei 
include lipopolysaccharide (LPS), capsule, quorum sensing proteins, and Types III and 
VI Secretion system components (reviewed by Galyov et al. 2010). 
B. mallei strain ATCC 23344 was the first strain reported to be fully  sequenced 
and its genome consists of two circular chromosomes (Nierman et al. 2004). 
Chromosome one is 3.5 Mb and encodes 3,344 coding sequences, with a large proportion 
of these coding for core functions of the bacteria including amino acid metabolism and 
protein biosynthesis. Chromosome two is 2.3 Mb and encodes 2,091 coding sequences, a 
higher proportion of which code for accessory functions such as virulence factors 
(Nierman et al. 2004; Whitlock et al. 2007). In addition, B. mallei has many insertion 
sequences, transposable inserts, horizontally-acquired genomic islands, and extensive, 




greater than 1000 predicted genes less than B. pseudomallei, the two organisms have 99% 
sequence identity in the genes that that they share (Galyov et al. 2010). It is widely 
believed that B. mallei recently evolved from a single clone of B. pseudomallei through 
genome downsizing by gene loss and insertion sequences (Godoy et al. 2003; Losada et 
al. 2010). Ten different strains of B. mallei have been either partially or fully sequenced 
and sequence data is available online (ncbi.nlm.nih.gov/genome/genomes/477?subset=). 
 
Section 1.1d Burkholderia thailandensis 
 Burkholderia thailandensis is a Gram-negative soil saprophyte closely related to 
B. pseudomallei. It is found endemically near B. pseudomallei in Southeast Asia, and was 
first isolated in Thailand (Brett et al. 1998). Originally it was considered to be a 
nonpathogenic subtype of B. pseudomallei that could not assimilate arabinose, but in 
1998 (Brett et al. 1998) it was recognized as its own species.  
 B. thailandensis has two chromosomes, 3.8 Mb and 2.9 Mb, with a total of 5,645 
predicted protein-coding ORFs (Yu et al. 2006). Five strains of B. thailandensis have 
been sequenced, including strain E264 used in this study 
(http://www.ncbi.nlm.nih.gov/genome/genomes/721?subset=) B. thailandensis and B. 
pseudomallei are broadly similar at many genomic levels, and they share many genes 
responsible for functions such as core metabolism and accessory pathways. Even 
bacterial virulence factors are conserved between the two species, although there is 




evolution in comparison to B. thailandensis (Yu et al. 2006). Because of this, B. 
thailandensis has been used as a model organism for the study of B. pseudomallei. 
(reviewed in Galyov et al., 2010). Genome comparison between the two organisms has 
helped to identify major B. pseudomallei virulence factors based on their absence or 
differences in B. thailandensis (Haraga et al. 2008; Galyov et al. 2010 and references 
therein).  
 Human cases of infection from B. thailandensis or B. thailandensis-related 
organisms are extremely rare and the clinical view is that this organism poses little 
danger to humans. It has, however, been shown that high intranasal inoculating doses 
(1x106 cfu, as compared to 1x103 cfu of B. pseudomallei) of B. thailandensis can cause 
fulminant, lethal infections in a mouse model of infection (Wiersinga et al. 2008). In fact, 
there are case studies that have found B. thailandensis infection in humans, including in 
an amputated knee in Thailand (Lertpatanasuwan et al. 1999), and a potential case of 
pneumonia and septicemia caused by B. thailandensis was reported in northeastern Texas 
(Glass et al. 2006). B. thailandensis infection is dependent on shared virulence factors 
with closely related species B. pseudomallei and B. mallei (West et al. 2008). There is 
evidence that these shared virulence factors, including LPS, Types III and VI Secretion 
systems, and quorum sensing molecules (reviewed by Galyov et al. 2010), contribute to 
intracellular spread in eukaryotic cells (Harley et al. 1998). After intranasal infection in a 
mouse model, the lungs are most commonly affected and the bacterium can spread to the 





SECTION 1.2 MELIOIDOSIS  
 
Section 1.2a Melioidosis Disease History, Transmission, Clinical Presentation and 
Progression 
 The disease melioidosis, previously known as Whitmore’s disease, was first 
discovered in Burma by Captain Alfred Whitmore, a British pathologist, and his assistant 
C.S. Krishnaswami in 1912 (Whitmore 1913). Independently, at the Institute for Medical 
Research in Malaysia, bacteriologist Ambrose Thomas Stanton and pathologist William 
Fletcher began to study an outbreak of "distemper-like" disease in animals. In 1917 
(Stanton and Fletcher 1932), the two scientists identified Bacillus pseudomallei as the 
causative agent of the disease. Stanton and Fletcher named the disease 'melioidosis' from 
the Greek, melis, which translates to 'distemper of asses,' and eidos, which translates to 
'resemblance' because of the strong resemblance of the disease to glanders (Stanton and 
Fletcher 1932).  
 There is a high prevalence of melioidosis in northeastern Thailand and northern 
Australia. In Thailand, there are an estimated 2,000-5,000 cases of melioidosis per year, 
though the number of cases is likely underreported (Dance 1991).  Melioidosis is the 
most common cause of community-acquired septicemia in Thailand, accounting for 20% 
of all septicemias. In parts of northern Australia melioidosis is the most common cause of 




et al. 2010).  
 Several predisposing conditions have been linked to melioidosis infection, and 
between 66-80% of melioidosis cases have underlying predisposing conditions 
(Suputtamongkol et al. 1999; Currie et al. 2000). The most common predisposing 
condition, diabetes mellitus with poor sugar control, is present in 37-60% of melioidosis 
cases in Australia and Thailand (Sarkar-Tyson and Titball 2010). Other predisposing 
conditions include chronic renal failure, immunosuppressive treatments, including 
steroids, thalassemia, chronic liver disease, chronic lung disease (including cystic 
fibrosis) and kava consumption (reviewed by Limmathurotsakul and Peacock 2011). 
Surprisingly, although HIV is also prevalent in Thailand, no link has been identified 
between melioidosis and HIV infection, and melioidosis patients who are HIV+ have 
similar outcomes to patients who are HIV- (Chierakul et al. 2004).   
  There are three generally accepted routes of melioidosis infection: inhalation, 
inoculation, and ingestion (Cheng and Currie 2005). While percutaneous inoculation 
following exposure to muddy soils or surface water is considered to be the natural 
infection route, it is thought that under certain environmental conditions, such as tropical 
storms, cyclones, and typhoons, inhalation is the main mode of infection (reviewed in 
Patel et al. 2011 and references therein). The inhalational route is also supported by 
observations during the Vietnam War that helicopter crews were frequently infected with 
B. pseudomallei due to the aerosols generated by the helicopter blades (Howe et al. 




after monsoons, and after the tsunami in 2004 (Chierakul et al. 2005). In fact, rainfall 
fourteen days before hospital presentation with melioidosis is a strong indicator of 
disease severity (Cheng and Currie 2005). Person-person or animal-animal spread 
through the respiratory route is very rare and not considered to be a mode of transmission 
(Limmathurotsakul and Peacock 2011).  
 From a well-defined exposure to B. pseudomallei, the incubation period for acute 
melioidosis is between 1-21 days, with a mean incubation time of 9 days (Currie et al. 
2000). Melioidosis is a febrile illness, and the most common presentation is pneumonia, 
with or without septicemia (Currie et al. 2000). Other common symptoms include 
superficial pustules and subcutaneous abscesses (Limmathurotsakul and Peacock 2011). 
The lungs are most commonly affected, and from the lungs the organism is spread 
throughout the body via macrophages (White 2003). The most common secondary sites 
of B. pseudomallei colonization include the liver, spleen, skin and soft tissues 
(Limmathurotsakul and Peacock 2011). Clinical patterns of the disease differ in Thailand 
and Australia. In Thailand, 30-40% of children who acquire melioidosis infections 
present with suppurative parotitis, which is not seen in Australia. In Australia, 
melioidosis can cause encephalomyelitis and, in 18% of infected males, can also cause 
genitourinary infection with prostatic abscesses. These manifestations have not been 
reported in Thailand (Cheng and Currie 2005; Limmathurotsakul and Peacock 2011).  
 Treatment of melioidosis is difficult. B. pseudomallei is intrinsically resistant to 




pneumonia and septicemia (Cheng 2010). In addition, B. pseudomallei has many 
mechanisms that it uses to exploit the host cells’ defenses and evade the immune system. 
The organism has the ability to overcome innate, cell-mediated, and antibody-mediated 
immunities, as well as the ability to invade and replicate inside both epithelial and 
phagocytic cells (reviewed by Galyov et al. 2010).  The mortality rate for melioidosis 
infection in Thailand is 40-50%, and it is the third most common cause of death from 
infectious disease there after HIV/AIDS and tuberculosis (Limmathurotsakul et al. 2010).  
In Australia the mortality rate is 15-19% (Cheng et al. 2008; Limmathurotsakul et al. 
2010). The difference in mortality is largely due to the inequality of intensive care 
facilities between the two areas (Limmathurotsakul et al. 2010).  
 Chronic infections are also seen in melioidosis. Chronic melioidosis has similar 
manifestations to disseminated fungal infection or tuberculosis (Weber et al. 1969). Not 
much is understood about the location or activities of the bacteria during latent infections, 
but it has been observed that in animal models, the bacteria are located in the lungs, liver 
and spleen (Dance 2005). Latent infection can reemerge after stresses such as illness or 
aging (Sanford 1978). The longest recorded latency of melioidosis infection was in a 
WWII veteran, where the infection recurred after a latent period of 62 years (Ngauy et al. 
2005). Many Vietnam War veterans who had contracted melioidosis during the war had 
recurrence of illness between 1-5 years after the initial event, mostly after a precipitating 
event such as an unrelated illness (Sanford 1978). Because of this, melioidosis has been 




melioidosis after a 36 year latency (Wells et al. 2011), and it is possible that there are 
veterans who yet have latent B. pseudomallei infections.  
 
Section 1.2b Melioidosis Treatment and Antibiotic Resistance 
 As previously noted, treatment of melioidosis is challenging. B. pseudomallei is 
intrinsically resistant to penicillins, cephalosporins, macrolides, rifamycins, colistin, 
aminoglycosides, quinolones, beta lactams, and polymixins (Wuthiekanun et al. 2011). 
The current protocol for antibiotic treatment of melioidosis includes an initial intensive 
intravenous phase followed by a prolonged oral eradication phase. The initial phase 
consists of either ceftazimide or carbapenem for 10-14 days, followed by 3-6 months of 
eradication with trimethoprim-sulfamethoxazole with or without doxycycline. Even with 
20 weeks of treatment the disease can still relapse in 5-25% of cases (Limmathurotsakul 
and Peacock 2011). 
 B. pseudomallei is also susceptible to silver carbene complexes in vitro, and could 
be used to treat infection (Panzner et al. 2009). Cationic liposome DNA (CLDC) has also 
been studied as a potent activator of innate immunity in a mouse model. It has been 
demonstrated that CLDC can provide nearly complete protection if it is administered via 
an intranasal route shortly after bacterial challenge (Goodyear et al. 2009). Interferon-" 
(IFN-") has also been used for the treatment of melioidosis. Previous reports indicate that 
IFN-" plays an important role in the host’s defenses against B. pseudomallei infection. 




inhibition of B. pseudomallei growth in macrophages (Propst et al. 2010).  
 
Section 1.2c Melioidosis Current Diagnostics 
 Culture of B. pseudomallei is the gold standard of melioidosis diagnostics (White 
2003). Isolation of even a single colony from a low quality sample may be enough to 
diagnose melioidosis, as any B. pseudomallei colonization is extremely rare (Walsh and 
Wuthiekanun 1996; Peacock 2006; Cheng 2010). Isolated growth of B. pseudomallei is 
ideally performed on Ashdown’s media (Ashdown 1979), which contains glycerol and 
gentamicin. Glycerol enhances the wrinkled appearance of the colonies, and gentamicin 
selects against many normal bacterial species. Ashdown’s media also contains a dye that 
is taken up into the colonies, and this facilitates presumptive identification of B. 
pseudomallei (Dance et al. 1989). Positive blood cultures take 48 h, but it can take up to 
5-7 days for culture confirmation (Weber et al. 1969; Cheng 2010). As acute melioidosis 
infection can be fatal within this time period, improved sensitive and specific diagnostic 
tests are necessary.  
 Many diagnostic tests exist for melioidosis, including latex agglutination, indirect 
hemagglutination (IHA), polymerase chain reaction (PCR), and immunofluorescence; as 
well as several commercially available kits. Each of these diagnostic tests has its own 
strengths and shortcomings.  
 Latex agglutination, an assay where monoclonal or polyclonal antibodies are 




shown to be highly sensitive and specific when used with a monoclonal antibody against 
B. pseudomallei polysaccharide capsule (Wuthiekanun et al. 2002). Although this assay is 
able to differentiate between B. pseudomallei and B. thailandensis (which lacks a 
capsule), the assay does not differentiate between B. pseudomallei and B. mallei, and it 
requires a bacterial culture to be performed, which does not increase the speed of 
diagnosis (Amornchai et al. 2007). However the test is inexpensive and technically 
simple, thus making it very amenable for use in developing countries where melioidosis 
is endemic (Amornchai et al. 2007). 
 IHA is the only widely used serological test for melioidosis, despite many reports 
of low sensitivity and specificity (Cheng et al. 2006). It is a simple and inexpensive test 
to perform, and it tests for antibodies against B. pseudomallei antigens in the blood. 
However, it has a high rate of false positives in endemic areas because many people are 
seropositive to B. pseudomallei as a result of environmental exposure (Cheng and Currie 
2005). In Thailand, 60-70% of children are seropositive according to IHA testing 
(Wuthiekanun et al. 2006) 
 There have been several reports of PCR assays for the detection of B. 
pseudomallei. The evidence for success of these assays is difficult to deduce because of 
many conflicting reports and difficulty of reproduction. PCR is an ideal medium for 
differentiating between B. pseudomallei and B. mallei, which is useful in the case of a 
bioterrorism event (Peacock 2006). A few genes that have been used in PCR diagnostic 




System, and recA (Suppiah et al. 2010). However, due to the high cost, PCR assays are 
not suitable for use in rural endemic areas, where Gram stains and immunofluorescence 
are much cheaper. PCR assays also have relatively low sensitivity from direct blood 
specimens because of the low bacterial load found in the blood (Cheng 2010).  
 Immunofluorescence is a very promising diagnostic assay for endemic areas. A 
one-step, rapid immunofluorescence assay has been developed that can detect B. 
pseudomallei in sputum, pus, or urine in under 30 min using fluorescence-labeled 
monoclonal antibodies raised against B. pseudomallei (Wuthiekanun et al. 2005). This 
assay is highly specific and fairly sensitive. Unfortunately, the monoclonal antibody used 
for this assay was produced in-house at the clinic where it was used, and the animal that 
provided the antibody is now dead.  This assay could easily be recreated with other 
monoclonal antibodies against B. pseudomallei, and with high quality antibodies the 
sensitivity and specificity would be greatly increased. This has been demonstrated on B. 
thailandensis using a commercially available B. mallei anti-LPS monoclonal antibody 
(Qazi et al. 2011). 
 Several commercial kits have been tested for their ability to diagnose B. 
pseudomallei. The API20NE test, a biochemical panel that relies on culture, has widely 
varying reports of sensitivity and specificity, but may be suitable for detection of certain 
strains of B. pseudomallei. The Vitek 1 and 2 automated identification systems have 
reliability issues in B. pseudomallei detection, and are therefore not ideal for diagnosis 




been found to be less specific and sensitive than culture, and the RapID NF Plus test, a 
culture-based biochemical panel, has been found to be ineffective (Peacock 2006). It has 
been surmised that the most cost effective and sensitive diagnostic tests for acute 
infections will involve direct detection of bacterial antigens or whole organisms (Qazi et 
al. 2011). 
 
Section 1.2d Melioidosis Vaccine Status 
 There is currently no vaccine available for melioidosis, though many strategies for 
vaccination have been investigated. Various levels of protection from B. pseudomallei 
infection have been observed for several of these strategies, but sterile immunity is rarely 
reported (Sarkar-Tyson and Titball 2010). One of the hurdles to an effective vaccine is an 
unresolved understanding of the protective innate and adaptive immune responses of the 
host (Whitlock et al. 2007). It has been speculated that a multicomponent vaccine will 
have the best protection against B. pseudomallei due to our current understanding of 
protective responses (Sarkar-Tyson and Titball 2010). Humeral and cell-mediated 
immunity, both intrinsic and acquired, are essential for protection (Whitlock et al. 2010).  
 As previously mentioned, several strategies for protection against B. pseudomallei 
infection have been investigated in mice, including passive transfer, heat-killed and 
attenuated vaccination, and subunit vaccination. Passive transfer is a protection strategy 
that uses antibodies as protective agents. There has been some success in passive transfer 




anti-capsule and anti-LPS antibodies has been shown to double survival time post 
challenge with B. pseudomallei (Nelson et al. 2004). Data on immunizations with heat-
killed B. pseudomallei are conflicting, but one study has found some sterilizing immunity 
using a heat-killed vaccination strategy (Sarkar-Tyson et al. 2009). Live, attenuated 
auxotrophic B. pseudomallei mutants have shown protection against challenge in mice, 
however, it seems unlikely that an attenuated mutant would be approved for use in human 
vaccines (reviewed in (Sarkar-Tyson and Titball 2010). Subunit vaccine development has 
identified several B. pseudomallei antigens that offer some level of protection. Capsule 
and LPS polysaccharides provide protection (Nelson et al. 2004) as well as recombinant 
B. pseudomallei proteins including LolC (Harland et al., 2007), and BimA, HcpI, and 
BopA (Whitlock et al. 2010). These five recombinant proteins all had 80% protection 
after 14 days, which is comparable to other studies (reviewed by (Patel et al. 2011). 
However, 60% of mice immunized with BopA survived 55 days post-infection, which 
makes BopA extremely promising for future vaccine work (Whitlock et al. 2010). Nieves 
et al. have reported a promising immunization approach against B. pseudomallei that 
utilizes bacterial derived outer membrane vesicles (OMVs). They have demonstrated that 
immunization with naturally shed B. pseudomallei OMVs provide significant protection 





SECTION 1.3  GLANDERS 
Section 1.3a Glanders Disease History, Transmission, Clinical Presentation and 
Progression 
 Glanders was first described by early Greek and Roman writers Aristotle, 
Apsyrtus, and Vegetius around BC 350, and Aristotle called the disease of horses mellis, 
or distemper of asses (Derbyshire 2002; Whitlock et al. 2007). The contagious nature of 
glanders was first described by the French veterinarian Solleysel in 1664, and by the 
early 19th century transmission of glanders from horse to human was well described in 
Europe (Derbyshire 2002). In 1882 B. mallei was identified as the causative agent of 
glanders from horse sputum by two independent groups; Loeffler and Shutz in Germany, 
followed by the French microbiologists Bouchard, Charrin, and Capitan (Derbyshire 
2002). Shortly afterwards, three groups independently developed the mallein skin test 
(described in section 1.3c) for specific diagnosis of glanders (reviewed by Derbyshire 
2002; Whitlock et al. 2007 and references therein).  
 Glanders was successfully eradicated from Great Britain, the United States, 
Canada, and all of Europe between 1928 to 1938 (reviewed by Derbyshire 2002). 
Eradication was tedious, as every animal was tested with the mallein skin test before 
entry to the country and infected animals were culled. In Canada alone, eradication took 
34 years, during which over 13,000 horses were killed and $1 million was spent in 
compensation for infected animals (Derbyshire 2002). While lower dependence on horses 
as a mode of transportation has decreased the incidence of glanders, recent outbreaks in 




Pakistan, Mongolia, China, Brazil and Bahrain (reviewed in Elschner et al. 2011). 
 Horses are the primary carriers of glanders, but donkeys and mules can also 
become infected when they come into contact with B. mallei in food and water that has 
been contaminated with infected sputum. In endemic regions, B. mallei infections have 
also been known to occur in other mammals including cats, dogs, bears, wolves and 
camels (Wernery et al. 2011 and references therein). Direct animal-animal transmission 
in horses is facilitated by crowding and by sharing food and water sources with 
glanderous animals (Galyov et al. 2010). Humans can become infected either by close 
interaction with infected animals or by laboratory exposure, but human glanders is 
extremely rare and human-human transmission has not been documented (Whitlock et al. 
2007). Glanders has not historically linked to predisposing conditions like melioidosis 
has, but the most recent case of laboratory-acquired glanders occurred in a diabetic man 
(Srinivasan et al. 2001). Laboratory-acquired glanders is more common than laboratory-
acquired melioidosis, leading to the suspicion that B. mallei is more infective than B. 
pseudomallei in the laboratory setting (Howe and Miller 1947). 
 Glanders is a febrile illness, and it can be either a chronic or acute disease. The 
chronic form is seen in horses, where it causes mucopurulent nasal discharge, lesions on 
the lungs, nodules in the liver and spleen, enlargement of lymph nodes, and pustules on 
the flanks and extremities (Whitlock et al. 2007; Galyov et al. 2010 and references 
therein). Discharge from the nose and pustules is infectious. Acute glanders is seen 




septum, and nasal discharge that is mucopurulent and sometimes hemorrhagic. Symptoms 
of human glanders have been reported as left axillary adenopathy, fever, fatigue, night 
sweats, malaise, rigors, and weight loss (Srinivasan et al. 2001).  
 Glanders was deadly before the invention of antibiotics, and it is extremely 
antibiotic resistant (Dance 2005). Treatment of glanders requires a prolonged course of 
antibiotics for eradication of the organism. Septicemic glanders has a 95% fatality rate in 
untreated cases, but for infections treated with antibiotics the fatality rate is still 50% 
(Whitlock et al. 2008).  
 
Section 1.3b Glanders Treatment and Antibiotic Resistance 
 B. mallei is intrinsically resistant to many antibiotics including penicillins, 
cephalosporins, macrolides, rifamycins, colistin, quinolones, beta lactams, and 
polymixins (Kenny et al. 1999; Thibault et al. 2004). Ceftazimide and levofloxacin are 
effective in vitro and in vivo against B. mallei for acute infection in a mouse model, but 
they fail to completely eradicate the bacterium, leading to a chronic, non-lethal form of 
glanders (Judy et al. 2009). Granulysin, a lytic peptide component found naturally in 
cytotoxic lymphocytes, may have potent lytic effects on B. mallei. Granulysin works by 
directly disrupting the microbial membrane by electrostatic charge disruption (Endsley et 
al. 2009). Silver carbene complexes are also effective in vitro against B. mallei and could 
be tested in vivo for activity during experimental glanders infections, which has not yet 




bacterial challenge with cationic liposome DNA (CLDC) has also been shown to protect 
from B. mallei infection by activating the innate immune system (Goodyear et al. 2009).  
 
Section 1.3c Glanders Current Diagnostics 
 Definitive diagnosis of glanders is made from isolation and identification of B. 
mallei from culture. B. mallei does not grow as well in culture as B. pseudomallei, and 
produces smooth, grey, translucent colonies. Most of the diagnostic tests for glanders are 
for use in horses and other equids, and there are not many diagnostic tests for glanders in 
humans (Dance 2005).  
 Historically the mallein test has been used to diagnose glanders in horses. The 
mallein test is similar to the tuberculin skin test, where mallein, a crude B. mallei cell 
extract, is injected subcutaneously or intradermally. Delayed hypersensitivity at the 
injection site is indicative of a positive mallein test (Derbyshire 2002). Mallein test 
sensitivity and specificity can vary depending on the type of mallein preparation.  
 The Complement Fixation Test (CFT) is the most valuable screening tool 
available for glanders in horses (Elschner et al. 2011), as it can detect carriers of the 
disease (Sprague et al. 2009). The assay is based on crude whole-cell preparations of B. 
mallei, which are used to detect anti-B. mallei antibodies in the horse’s serum. CFT has 
97% sensitivity compared to culture (Neubauer et al. 2005). False positive results occur 
in about 1% of tests, and could be due to cross reactivity with strangles, equine influenza, 




out (Sprague et al. 2009). 
 
Section 1.3d Glanders Vaccine Status 
 There is no animal or human vaccine for glanders, however studies to develop 
vaccines are ongoing (Peacock et al. 2012). One of the hurdles to an effective vaccine is 
an unresolved understanding of the protective innate and adaptive immune responses of 
the host (Whitlock et al. 2007). It is understood that both humoral and cell-mediated 
immune responses are essential for protection against B. mallei infection (Whitlock et al. 
2008). Live attenuated strains of B. mallei as well as heat killed cells may be good 
vaccines (Whitlock et al. 2007), and several proteins have been investigated for use in a 
subunit vaccine. Among the proteins that have been shown to be protective are LolC, 
BimA, HcpI, and BopA, with BopA demonstrating the best protection (Whitlock et al. 
2010). Because of its nature as an intracellular pathogen, sterilizing immunity is difficult 
to achieve.  
 
SECTION 1.4  PROTEIN TARGETS  
 
Section 1.4a FliC, BPSL_3319 
 Flagella are long, hair-like structures that extend from the surface of many 
bacterial species. They are mainly used for swimming motility, but they can also be used 




subunit that makes up the flagellar structure, and there are thousands of copies of the FliC 
protein present in bacterial flagella (Aldridge and Hughes 2002).  
 Within the pathogenic Burkholderia species, B. pseudomallei is motile via a polar 
tuft of flagella, and B. mallei is non motile and non-flagellated. While B. mallei do have 
an intact copy of the fliC gene, a gene upstream in the flagellar biosynthesis pathway, 
fliP, is disrupted, leading to no flagella being made (Nierman et al. 2004). This makes 
FliC an ideal diagnostic target, as reagents recognizing the bacterial flagella would be 
able to differentiate between B. pseudomallei and B. mallei. While this differentiation is 
less important in natural cases because of the low rate of human glanders, it could be very 
important in the event of an intentional bioterrorism release. 
 B. pseudomallei FliC is well-known to be immunogenic during melioidosis 
infection, with anti-flagellin antibodies present during infection (Felgner et al. 2009). It 
has also been indicated as a virulence factor, and mutant strains of B. pseudomallei that 
do not produce flagella are attenuated in virulence (Chua et al. 2003; Wikraiphat et al. 
2009). It has been suggested that flagella are involved in macrophage invasion 
(Chuaygud et al. 2008). In diagnostics, a recombinant, truncated FliC was successfully 
used as a probe against sera from melioidosis infection in ELISA, detecting anti-flagellin 
antibodies produced during active disease (Chen et al. 2003). The fliC gene has also been 
used in PCR-based diagnostic assays, which have their own drawbacks (Section 1.2c) 
(Sonthayanon et al. 2002; Tomaso et al. 2004; Tomaso et al. 2005). Because of its 




which showed protection against infection (Chen et al. 2006). Additionally, 
glycoconjucates of FliC with the O-polysaccharide moiety from B. pseudomallei  have 
been shown to be protective in the diabetic rat model of disease (Brett and Woods 1996) 
 
Section 1.4b PilA, BPSL_0782 and FimA, BPSL_1801 
 Type IV Pili (TFP) are surface structures found on a large variety of Gram-
negative bacteria as well as a couple of Gram-positive species. They are thin, flexible 
fibers that are 6-8 nm wide and several micrometers long, and they often aggregate into 
bundles. Because of their location and structure, TFP are involved in a number of 
functions including host-cell adhesion, biofilm formation, and twitching motility (Proft 
and Baker 2009). TFP are homopolymers composed of thousands of copies of the pilin 
subunit PilA, a small 17 kDa protein (Craig et al. 2004).  
 It has been demonstrated that TFP are expressed during infection with B. mallei 
(Fernandes et al. 2007) and that they are highly immunogenic, but immunization with 
PilA is not protective. TFP are involved in adherence of B. pseudomallei to host cells, 
and are therefore a potent virulence factor in infection (Essex-Lopresti et al. 2005; 
Boddey et al. 2006).  
 Fimbrae are much like pili. They are long, proteinaceous structures that extend 
from the surface of the bacterium (Dodd et al. 1984). Fimbrae are comprised of many 
helically-arranged identical subunits of the FimA protein (Brinton 1965) It has been 




(Nandi et al. 2010) 
 
Section 1.4c LolC, BPSL_2277 
 The LolABCDE complex is responsible for the transport of lipoproteins from the 
cytoplasm to the outer membrane in Gram-negative bacterial species. The LolCDE 
complex is an ATP-Binding Cassette (ABC) transporter that is responsible for moving 
lipoproteins from the cytoplasm, across the inner membrane, and into the periplasmic 
space using energy from ATP (Narita 2011).  From there the hydrophobic lipoprotein is 
shuttled through the hydrophilic periplasm via LolA and passed to LolB in the outer 
membrane, where it is flipped to the outer leaflet of the membrane (Narita 2011). The Lol 
system is well conserved in Gram-negative bacteria, and disruption of this system is 
lethal in Escherichia coli (Harland et al. 2007).  
 The LolCDE complex is generally composed of four parts: one copy of the LolC 
protein, one copy of the LolE protein, and two copies of the LolD protein. LolCDE is 
directly involved with ATP hydrolysis necessary to transfer the lipoprotein to LolA as 
well as the recognition of sorting signals on peptides (Narita 2011). LolC is an integral 
membrane protein, spanning the inner bacterial membrane 4 times. In addition, it has a 
large periplasmic domain between the first and second transmembrane helices, composed 
of amino acid residues 44-266 (Harland et al. 2007; Narita 2011).  In the LolCDE 
complex, LolC is responsible for the direct transfer of the lipoprotein to LolA.  




(Harland et al. 2007).  It has repeatedly been shown to have protective qualities against 
multiple strains of B. pseudomallei as well as against B. mallei (Harland et al. 2007; 
Whitlock et al. 2010).  The protective qualities of LolC are due to its ability to initiate a 
cell-mediated immune response in the host (Tippayawat et al. 2009) through the 
activation of T cells, and they are conserved across many Burkholderia species including 
B. pseudomallei, B. mallei, B. thailandensis, and Burkholderia cepacia (Tippayawat et al. 
2011).  
 
Section 1.4d BopA, BMA_1521 
 The type-three secretion system (T3SS) of B. mallei is involved in the 
translocation of effector proteins into the host-cell cytoplasm (Ulrich and DeShazer 
2004). The genome of B. mallei contains two T3SS and the genome of B. pseudomallei 
contains three T3SS (reviewed in Galyov et al. 2010). This assists the bacterium in 
invading the host defenses and also allows it to survive in the intracellular environment. 
Many of the intracellular virulence functions of B. mallei, including replication, are 
dependent on a functional T3SS. BopA is one of these T3SS effector proteins, and it is 
likely involved in replication inside the host cell (Whitlock et al. 2009).  
 Mutant strains of B. pseudomallei deficient in BopA have demonstrated an 
increased time to death in infection (Whitlock et al. 2009). Immunization with BopA 
protein from B. mallei, has demonstrated protective properties during experimental 




of infection (Whitlock et al. 2010).  
 
Section 1.4e SodC, BMA_0713 
SodC is an outer-membrane superoxide dismutase enzyme that has been reported to 
act on exogenous, host-generated reactive oxygen species in a Cu2+ and Zn2+ dependent 
manner (Vanaporn et al. 2011). Because of this, SodC has been linked to virulence in 
many species of bacteria including M. tuberculosis, Neisseria meningitidis, Vibrio 
vulnificus, and B. cepacia (Vanaporn et al. 2011). In addition, SodC mutants of 
Salmonella enterica serovars Typhimurium, Cholerasuis and Dublin, have demonstrated 
attenuation in mice. SodC has recently been shown to be a key virulence factor in B. 
pseudomallei, where it is important for survival in host macrophages (Vanaporn et al. 
2011).  
 
Section 1.4f pIII Protein 
 Phage M13K07 is a derivative of the M13 filamentous phage that is generally 
used for phage display during selection of fragment antibodies (fABs). The pIII protein, 
the product of the g3p gene of the phage, is essential for propagation of the phage by 
being directly involved in the infection of the host bacteria (Holliger et al. 1999). There 
are 3-5 copes of the pIII protein located at one end of the virion. In phage display, these 
are engineered to also express fAB sequences, and these fABs interact with the target 




strong affinity of the naked phage (with no fABs present) to the LolC-t protein was 
noticed (M. Rani, unpublished data). It was then hypothesized that the pIII protein was 
responsible for the affinity, and this work attempts to characterize this high affinity 
binding.  
 
Section 1.5  Project Aims 
  The aims of this project are to clone, express, and purify target proteins 
that have been identified as surface located or immunogenic by bioinformatic or 
experimental means. Specifically for this work, these protein targets include FliC, PilA, 
FimA, LolC, and BopA. Protein targets that have potential as diagnostic targets will be 
used for the selection of highly selective and specific diagnostic reagents: RNA aptamers, 
fragment antibodies (fABs), or commercially-produced monoclonal antibodies. High 
specificity and selectivity is important for rapid and accurate diagnosis of melioidosis and 
glanders without cross-reactivity to other organisms that could cause similar diseases in 
the endemic areas. These reagents will also then be used in the development of a novel 
diagnostic assay for melioidosis and glanders infections. Protein targets will also be 






Chapter 2: Materials and Methods 
 
SECTION 2.1  CHEMICAL REAGENTS 
 Chemicals were purchased from Fisher Scientific (Fair Lawn, NJ) and Sigma-
Aldrich (St. Louis, MO). Kanamycin, ampicillin, and chloramphenicol were from Sigma-
Aldrich (St. Louis, MO) and carbenicillin was from Carbenicillin Direct (United 
Kingdom). IPTG was from Gold Biotechnology (St. Louis, MO). Oligonucleotides were 
synthesized by Integrated DNA Technologies (IDT) (Coralville, Iowa). Expand Long 
Template High Fidelity Taq/Tgo polymerase mixture and Complete EDTA-Free protease 
inhibitor were from Roche (Indianapolis, IN), Taq polymerases were from Qiagen 
(Maryland) and NEB (Ipswich, MA), and Q-buffer and Ni2+-NTA were from Qiagen 
(Maryland). Restriction enzymes and T4 DNA ligase were from NEB (Ipswich, MA). 
DNA molecular weight standards were from Bioline (Tauton, MA) and NEB (Ipswich, 
MA). Magnetic beads were from Millipore (Temecula, CA) and Bangs Laboratories 
(Fishers, IN). pEXP5/TOPO TA expression kit was from Invitrogen (Carlsbad, CA). 
Protein molecular weight markers, Sodium Dodecyl Sulfate (SDS), molecular grade 
agarose, tetraethylmethyldiamide (TEMED), nitrocellulose membrane, were from 
BioRad (Hercules, CA). 30% Bis-Acrylamide mixture, Nunc Maxisorp microtiter plates, 
and Coomassie Brilliant Blue stain were from Sigma Aldrich (St. Louis, MO). Dry 




filters were from Millipore (Temecula, CA). Mouse monoclonal Anti-polyhistidine 
peroxidase antibody, Streptavidin-Peroxidase Polymer- Ultrasensitive, and 4-chloro-1-
naphthol were from Sigma (St. Louis, MO). 1-Step Ultra TMB ELISA reagent and 
biotinylation reagents were from Thermo Scientific (Rockford, IL). Dialysis tubing and 
dialysis clamps were from Spectrum Laboratories (Rancho Dominguez, CA). 
 
SECTION 2.2  MEDIA 
 Luria-Bertani Broth (LB broth) was made with reagents from Fisher Scientific 
(Fair Lawn, NJ) according to published protocols (Sambrook et al. 1989). LB media is 
composed of 1% (w/v) tryptone, 0.5% (w/v) yeast extract, and 0.5% (w/v) NaCl and 
media was sterilized by autoclaving (15 min at 120 ˚C, 1.5 Bar pressure) and stored at 
room temperature.  
 Luria-Bertani agar (L-agar) consisted of LB supplemented with 2% (w/v) agar. 
Appropriate antibiotics were added as needed: 100 !g/mL carbenicillin and 50 !g/mL 
kanamycin.  
 Overnight Express Instant TB Medium (OE), an autoinduction medium, was 
purchased from Novagen (Darmstad, Germany). This medium contains components that 
automatically induce protein expression from lac-based promoters in a time-released 
manner. The OE was prepared according to manufacturer’s specifications, sterilized by 




SECTION 2.3  BACTERIAL STRAINS 
 Five Escherichia coli strains were used in this study (Table 2.1). All strains were 
grown in either LB or OE. In addition, three Burkholderia strains were also used in this 
study (Table 2.1). All Burkholderia strains used in this study have been fully sequenced 
and the sequence data is available through online databases at www.burkholderia.com 
(Winsor et al. 2008).  
 E. coli strain DH5" allows excellent propagation of plasmid vectors. The endA- 
mutation knocks out the EndA endonuclease allowing for preparation of high quality 
plasmid DNA with lower levels of plasmid degradation. 
 E. coli BL21 (DE3) strains are deficient in proteases and designed for high level 
protein production from T7 RNA polymerase-based expression systems. These strains are 
naturally deficient in the Lon protease and are engineered to be deficient in the OmpT 
protease, both of which may cause degradation of recombinant proteins if present. The 
IPTG-induced expression of T7 RNA polymerase gene, which was integrated into the 
bacterial chromosome by DE3 # phage, allows expression of the plasmid-encoded gene 
to be tightly regulated. BL21_Star™ (DE3) has a mutation in the RNaseE gene, rne131, 
which is responsible for most mRNA degradation. BL21_Star™ (DE3) pLysS is 
designed to have low basal levels of heterologous gene expression and is designed for the 
expression of proteins that may be toxic to the E. coli host. Codon bias between 
recombinant genes and E. coli hosts can leave the tRNA pools depleted in the host 
leading to translational stalling, premature translation termination, translation 




of BL21 provides additional copies of rare tRNA genes on the pRARE plasmid that 
contains the argU, ileX, leuW, proL, and glyT genes that code for tRNAs that recognize 
the codons AGG/AGA, AUA, CUA, CCC, and GGA, respectively. 
The bacterial strain OQ-Rosetta-BopA114, a modified form of BL21_Rosetta (DE3) 
containing the pET-28a(+)-OQBOPA114 construct, was obtained as a gift from Dr. Omar 
Qazi. This strain was used to express and purify BopA-t protein. 
 B. pseudomallei strain K96243 and B. mallei strain ATCC 23344 were not 
directly used, but genomic DNA from these strains was obtained as a gift from Dr. 
Alfredo Torres at the University of Texas Medical Branch in Galveston, Texas. B. 
thailandensis strain E264 was used for genomic DNA extraction by Dr. Annie Gnanam at 
The University of Texas at Austin, Austin Texas, and the obtained genomic DNA was 
used as template for PCR. Heat-killed B. pseudomallei K96243 and B. thailandensis 
E264 as well as live B. thailandensis E264 were also used in ELISAs.    
 B. pseudomallei strain Bp82, a gift from Dr. Herbert Schweizer is an attenuated 











SECTION 2.4  PLASMIDS 
 All plasmids in this study have a T7 promoter and are IPTG inducible. 
 The pET-28a(+) plasmid (Novagen; Figure 2.1a) is an expression vector that 
confers kanamycin resistance and allows for expression of recombinant protein with 
either an N-terminal or C-terminal polyhistidine affinity tag. 
 The pET-15b plasmid (Novagen; Figure 2.1b) and the pEXP5-NT/TOPO 
plasmid (Invitrogen; Figure 2.1c) are expression vectors that confer carbenicillin 
resistance and incorporate an N-terminal 6x polyhistidine onto recombinant proteins 
expressed using it. 
 Plasmid pET-15b-OQFLICR containing a truncated portion of the FliC gene from 
B. pseudomallei strain K96243 (BPSL_3319) was obtained as a gift from Dr. Omar Qazi 
(UT Austin). This construct was designed based on the crystal structure of the S. 
typhimurium flagellin structure (1UCU). The FliC construct Qazi5-6 was designed to 
remove the oligimerization domains comprised of both the C- and N-termini. This 
plasmid has a pET-15b backbone with DNA sequence corresponding to amino acid 
residues 175-297 cloned between the NdeI and BamHI sites in the multiple cloning 
region of the plasmid (Figure 2.2a).  
 Plasmid pET-15b-OQFIMA containing a truncated portion of the FimA gene 
(BPSL_1801) from B. pseudomallei strain K96243 was obtained as a gift from Dr. Omar 
Qazi (UT Austin). This construct, Qazi7-8, is in the pET-15b plasmid with the DNA 
sequence corresponding to residues 21-170 of the FimA protein inserted between the 
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 Plasmid pET-28a(+)-OQLOLCN containing a truncated form of the LolC gene 
(BPSL_2277) from B. pseudomallei K96243 was obtained as a gift from Dr. Omar Qazi 
(UT Austin). This construct, is in the pET-28a(+) plasmid with the DNA sequence 
corresponding to residues 44-266 of the protein inserted between the NdeI and BamHI 
sites in the multiple cloning region of the plasmid, adding an N-terminal  
polyhistidine tag (Figure 2.2c). 
 The helper phage M13K07 was obtained from NEB (Ipswich, MA). This phage is 
a derivative of M13 filamentous phage that has a mutation at the origin of replication to 
add a kanamycin resistance gene and a P15A origin of replication from E. coli. This 
helper phage is often used for phage display to select antibody fragments (fABs) against 
molecular targets. In this project, however, it was used for PCR and cloning without 

















































SECTION 2.5  COMPETENT CELLS 
 5 mL of LB broth were inoculated from a glycerol stock of the relevant strain of 
E. coli and grown overnight at 37 ˚C with 250 rpm shaking. 20 mL of LB broth were then 
inoculated with 500 !L (1:50 dilution) of the overnight culture and grown at 37 ˚C with 
250 rpm shaking until the Optical Density at 600 nm (OD600) reached 0.6. Cells were 
centrifuged at 3,000 x g for 5 min and resuspended in 30 mL cold, sterile 10% (v/v) 
glycerol. Cells were pelleted again at 3,000 x g for 10 min and the supernatant removed 
and replaced with 30 mL fresh cold, sterile 10% glycerol. This wash was performed twice 
more for a total of three washes. The resulting cell pellet was resuspended in 500 !L of 
cold, sterile 10% glycerol, divided into 85 !L aliquots in 1.5-mL microfuge tubes, and 
stored at -80 ˚C. Competent cells were thawed on ice as needed. 
 
SECTION 2.6  TRANSFORMATION 
 100 ng of purified plasmid or 30 !L of cleaned ligation product (Section 2.13) 
were added to 85 !L of competent cells (Section 2.5) and transferred to an 
electroporation cuvette (BioRad, Hercules, CA). The mixture of cells and DNA was pulse 
electroporated at 1800 V and transferred to 1.5 mL of LB broth and grown at 37 ˚C with 
shaking at 250 rpm for one h. Cells were centrifuged for 2 m at 240 x g and the 
supernatant discarded. Cell pellets were resupended in 110 !L LB broth. 100 !L of this 
suspension was spread neat onto L-agar plates containing the relevant antibiotic. The 
remaining 10 !L was diluted by the addition of 90 !L of LB broth and spread on L-agar 




overnight and visually scanned for transformed colonies. Bacteria that had incorporated 
the plasmid carried the antibiotic resistance gene and could grow on the antibiotic-
containing media, whereas non-transformed colonies did not have the antibiotic 
resistance gene and would not survive on the antibiotic-containing media. 
 
SECTION 2.7  GROWTH OF CULTURES  
 All cultures were supplemented with antibiotics as required. L-agar plates were 
streaked with cultures and incubated at 37 ˚C overnight. Liquid cultures were grown in 
standard glass or plastic baffled flasks with shaking at 250 rpm at 37 ˚C or 18 ˚C. 
Glycerol stocks were prepared by inoculating 5 mL of LB broth with a single colony and 
growing overnight 37 ˚C with shaking. 420 !L of sterile 50% (v/v) glycerol were added 
to 1 mL of overnight culture, vortexed to mix, and frozen at -80 ˚C for long-term storage. 
 
SECTION 2.8  PRIMER DESIGN 
 Targets were chosen using proteomics, bioinformatics, comparative genomics and 
data from previously published work. Specific gene sequences for Burkholderia genes 
were obtained from CMR (Peterson et al. 2001), burkholderia.com, (Winsor et al. 2008), 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa 2000). These 
sequences were analyzed using the programs Signal P 3.0 (Bendtsen et al. 2004), 
TMHMM 2.0 (Krogh et al. 2001), and PHYRE or PHYRE 2 (Kelley and Sternberg 2009) 




was analyzed for restriction sites using NEBcutter 2.0 (Vincze et al. 2003) or by using a 
built-in application in the Geneious Pro program (Drummond et al. 2011). Primers for 
pET-28a and pET15-b constructs consisted of 18-25 nucleotides corresponding to the 
beginning or the end of the sequence to be amplified along with insertions for the 
indicated restriction sites and, if not supplied by the plasmid, the insertion of a stop codon 
at the terminus of the sequence. Primers were flanked by random nucleotide sequences 4-
5 nucleotides long to protect the restriction site from degradation. Primers for cloning in 
the TOPO system typically contained 18-25 nucleotides corresponding to the sequence of 
the gene, and the insertion of a termination codon at the end of the reverse primer. 
Primers were analyzed for melting temperature using OligoAnalyzer 3.1 on the IDT 
website, www.idtdna.com (Owczarzy 2005). Primer sequences were adjusted in length so 
that the forward and reverse primer melting temperatures were within 4 ˚C of one another 
and preferably in the range of 60-65 ˚C (Table 2.2).  
 
 
Table 2.2 Oligonucleotide primers used in this study 
SECTION 2.9  AGAROSE GEL ELECTROPHORESIS  




powder in 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA) in a microwave. Gels 
contained 0.5 !g/mL ethidium bromide and were cast horizontally for either the Hoefer 
HE 33 Mini Horizontal Submarine Unit (40 mL) or the Owl Separation Systems D3 (100 
mL). Gels were run in a tank containing 1x TAE buffer. DNA samples were mixed 1 in 6 
with loading buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF, 30% 
(v/v) glycerol in water) and loaded into the gels wells. Electrophoresis was typically 
performed at 100 V for 1 h.  
 
SECTION 2.10 PURIFICATION OF DNA 
 DNA purification was performed in two ways. 
 DNA to be purified by Gel Extraction was electrophoresed in a 0.8% (w/v) 
agarose gel (Section 2.9). The gel band containing DNA of the correct size, as 
determined by visual examination next to a known molecular weight ladder, was excised 
with a sterile blade, placed in a microfuge tube and weighed to determine how much 
reagent to add to dissolve the agarose. The DNA was purified from the gel band using the 
QIAquick Gel Extraction Kit (Qiagen, Maryland) according to the manufacturer’s 
instructions and eluted in 30-50 !L sterile water (Qiagen, Maryland). 
 DNA was also purified with the QIAquick PCR Purification Kit (Qiagen, 






SECTION 2.11 PREPARATION OF PLASMID DNA  
 Plasmid DNA was purified from 5-10 mL bacterial cultures grown in LB broth 
using the QIAprep Spin Miniprep Kit (Qiagen, Maryland) according to the 
manufacturer’s instructions. Plasmid DNA was eluted in 30-50 !L sterile water for short 
term-storage or in elution buffer provided for long-term storage. 
 
SECTION 2.12 DNA DIGESTION WITH RESTRICTION ENZYMES  
 1 !g of DNA was digested in a final volume of 40-60 !L. The DNA, 10x enzyme 
buffer (supplied with the enzyme by NEB, Ipswich, MA), restriction enzymes, and water 
were gently mixed together and incubated at 37 ˚C in a water bath. The duration of 
incubation depended on the enzymes used, and varied from 2 h to overnight. 
 
SECTION 2.13 DNA LIGATION  
 Ligations were generally performed in volumes of 30-50 !L with buffer supplied 
the enzyme (NEB, Ipswich, MA). The weight ratio of vector to insert was 1 to 3, and a 
minimum of 100 ng of vector was used. After the ligation, the ligation mixture was 
subjected to a PCR purification (Section 2.10) and eluted from the spin column in 30 !L 
sterile water. 
 
SECTION 2.14 TOPO CLONING  




instructions in 6 !L using 3 !L of cleaned PCR product (Section 2.10), 1 !L provided 
salt solution, 1.5 !L sterile water, and 0.5 !L of the TOPO vector. Plasmid was then 
transformed into provided One Shot chemically competent E. coli cells by heat shock, 
grown in provided S.O.C. medium at 37 ˚C with shaking for 1 h, and spread on L-agar 
plates with carbenicillin for overnight selective growth.  
 
SECTION 2.15 DNA CONCENTRATION  
 DNA concentration was determined using a Nanodrop 2000 Spectrophotometer 
(Thermo Fisher, Wilmington, DE). 2 !L of DNA were loaded onto the instrument and the 
absorbance was measured at a wavelength of 260 nm. Software included with the 
machine calculates the analyte concentration using a modified version of Beer’s Law, c = 
(A * e)/b Where c is the nucleic acid concentration in ng/!L, A is the absorbance in AU, 
e is the extinction coefficient in ng-cm/!L and b is the path length in cm. The generally 
accepted extinction coefficient for double stranded DNA is 50 ng-cm/!l and for single 
stranded RNA is 40 ng-cm/!l. This calculation gives the concentration output in ng/!L. 
 
SECTION 2. 16 POLYMERASE CHAIN REACTION 
 DNA sequences were amplified using the polymerase chain reaction (PCR). 
Templates were typically genomic DNA from B. pseudomallei K96243, B. mallei 23344, 
and B. thailandensis E264 (Section 2.3), but also included M13K07 filamentous phage 




polymerase or Expand Long Template High Fidelity Taq/Tgo polymerase mixture 
(Section 2.1). 
 Amplification with either polymerase type was performed in volumes ranging 
from 10 !L to 100 !L. The PCR reactions generally contained 10% (v/v) of the provided 
10x PCR buffer, 20% (v/v) of the Q buffer, if necessary (Qiagen, Maryland), 200 !M 
dNTP mixture, about 1 U of Taq/10!L of reaction, and approximately 1.5 ng of genomic 
DNA per 10 uL reaction. Amplification thermalcycler programs varied by the length of 
DNA to be replicated and the melting temperature of the specific primers used (Table 
2.2). The general outline of the thermalcycler program was:  
1. 94 ˚C for 5:00 
2. 94 ˚C for 0:30 
3. Annealing temperature and time varied by construct 
4. 72 ˚C, time varied by construct 
5. Repeat steps 2-4 29 times for a total of 30 cycles.  
6. 72 ˚C for 10:00 
7. 4 ˚C indefinitely 
 Agarose gel electrophoresis (Section 2.9) was used to verify amplification for a small 
scale PCR before moving on to larger volumes.  
 
SECTION 2.17 DNA SEQUENCING 
 Recombinant plasmids grown in E. coli DH5" were purified as described above 
(Section 2.11). Purified plasmids were sent to the DNA Sequencing Facility in the 
Institute for Cellular and Molecular Biology at the University of Texas at Austin. 




machine with T7 sequencing and terminating primers (Table 2.3), added by the staff in 
the facility as indicated upon sample submission. 
 
 
Table 2.3 Sequencing Primers used in this study 
 
SECTION 2.18 DNA SEQUENCE ANALYSIS 
 DNA sequences obtained post-sequencing from the DNA Sequencing Facility 
were analyzed against available genomic data using the program Geneious Pro (83).  
 
SECTION 2.19 PROTEIN EXPRESSION OPTIMIZATION 
 Plasmids confirmed to contain the correct insert from DNA sequencing were 
transformed into E. coli BL21 strains (Section 2.6) for expression studies. Colonies were 
picked and grown in 5 ml LB broth overnight with the indicated antibiotics at 37 ˚C with 
250 rpm shaking. On the following day, 50 !L of each overnight culture were added to 5 
mL of LB broth containing the appropriate antibiotics and allowed to grow at 37 ˚C with 
shaking until an OD600 of 0.6 was reached. Cultures were then induced with either 1.0 or 




were collected at 2 h, 4 h, 6 h and overnight for the 37 ˚C cultures, and at 6 h and 
overnight for the 18 ˚C cultures. Samples were spun down at 20,800 x g for 5 min, pellets 
were lysed by boiling with loading buffer, and were then run on SDS PAGE gels and 
visually analyzed for large overexpressed protein bands near the predicted protein size. 
Promising conditions were then scaled up to 100-mL cultures to test of solubility of the 
protein. 100 mL of LB broth plus antibiotic were inoculated with 1 mL overnight culture 
and grown under previously specified conditions. After growth cultures were spun down 
at 2,000 x g for 20 min, pellets were resuspended in 5 mL of lysis buffer. Cells were 
lysed by sonication (Misonix sonicator 3000; power level 7, 30 s pulse, wait/delay 30 sec, 
total time 3 min with a microtip probe), and insoluble material was removed by 
centrifugation at 19,118 x g for 40 min. Supernatant containing soluble proteins was 
decanted from the pellet, and small amounts of pellets were resuspended in 1x PBS and 
run alongside supernatants on SDS-PAGE gels (Section 2.29). Western blots were also 
performed to verify the expressed protein was present in the soluble portion (Section 
2.30).  
 When proteins failed to express in soluble form using LB medium and then 
inducing with IPTG, expression was tested in Overnight Express Instant TB media (OE). 
OE was inoculated from single colonies isolated from LB agar plates or from glycerol 
stocks and grown at 37 ˚C with shaking overnight. Cell pellets were resuspended in 1x 
PBS and boiled with gel loading dye to lyse and run on SDS-PAGE gels. Gels were 




presence of a band of the predicted molar mass were then tested for solubility as 
described in Section 2.19.  
 
SECTION 2.20 PROTEIN EXPRESSION IN LB BROTH 
 For expression in LB broth, 25 mL overnight cultures per 1-L expression culture 
were set up a day prior to the expression in LB broth containing indicated antibiotics and 
grown with shaking at 37 ˚C overnight. The next morning 6-L flasks each containing 2 L 
of autoclaved sterilized LB broth were inoculated with 40 mL of the overnight culture 
and grown with appropriate antibiotics until an OD600 of 0.6 was reached, approximately 
3 h. At this point cultures were induced with IPTG to a final concentration of either 1.0 
mM or 0.1 mM, based on previous expression studies. Cultures were grown with shaking 
at the temperature and time previously determined and cells were then pelleted 2,600 x g 
for 30 m in a fixed-angle rotor. Supernatants were discarded and cell pellets were either 
used immediately for protein purification or frozen at -20 ˚C until purification could be 
performed. 
 
SECTION 2.21 PROTEIN EXPRESSION IN OVERNIGHT EXPRESS MEDIA 
 For expression in OE, microwave sterilized OE was added to autoclaved plastic 
baffled flasks at 1/10th of their volume for aeration.  OE was then inoculated from 
glycerol stocks and grown overnight at 37 ˚C with shaking and cells were pelleted by 




were discarded and cell pellets were either used immediately for protein purification or 
frozen at -20 ˚C until purification could be performed. 
 If 18 ˚C growth was desired, 5 mL overnight cultures were first grown in OE at 
37 ˚C. Overnight cultures were then used to inoculate fresh OE as above. This culture 
was grown for 4 h at 37 ˚C, then moved to 18 ˚C for 24 h. Cells were pelleted as in the 
previous paragraph. 
 
SECTION 2.22 BOILATE PREPARATION 
 Whole cell boilates were prepared from 500 !L - 1 mL samples taken from liquid 
bacterial cell culture. Samples were centrifuged at 2700 x g for 2 min to pellet cells. Cells 
were resuspended in 100 $ 200 !L PBS, and 6x protein sample buffer  [125 mM Tris-
HCL pH 6.8, 2% (w/v) SDS, 10% (v/v) %-mercaptoethanol, 0.9% (w/v) bromophenol 
blue, 45% (v/v) glycerol] was added appropriately. Samples were heated in a 90 ˚C heat 
block for 5 min. Prior to gel loading, samples were centrifuged at 17, 900 x g for 5 min to 
pellet insoluble material.  
 
SECTION 2.23 SMALL SCALE PROTEIN PURIFICATION 
 Cell pellets obtained from Sections 2.20 or 2.21 were resuspended in 25-50 mL 
imidazole lysis buffer (2.6 mM NaH2PO4, 47.3 mM Na2HPO4, 500 mM NaCl, 10 mM 
imidazole, pH 8.0) with Complete protease inhibitor (Roche). Cells were lysed by 




4 m with a microtip probe), and insoluble material was removed by centrifugation at 
19,118 x g for 40 min. Supernatant containing soluble proteins was decanted from the 
pellets and added to 0.5-1 mL washed and equilibrated Ni2+-NTA agarose beads and left 
to incubate for 1 h at 4 ˚C with agitation. After incubating, the Ni2+-NTA was allowed to 
settle and the remaining lysate was pipetted off the resin. Ni2+-NTA agarose was washed 
with several volumes of imidazole wash buffer (2.6 mM NaH2PO4, 47.3 mM Na2HPO4, 
500 mM NaCl, 25 mM imidazole, pH 8.0). After the last of the wash buffer was added, 
resin was loaded onto a small disposable column (BioRad). After all remaining wash 
buffer had flown through the resin, protein was eluted off of the Ni2+-NTA by adding 0.5-
1.5 mL imidazole elution buffer (2.6 mM NaH2PO4, 47.3 mM Na2HPO4, 500 mM NaCl, 
200mM imidazole, pH 8.0) and allowing it to flow through the resin and out of the 
column.  The eluted material was then collected and allowed to pass through the resin an 
additional time in order to maximize protein recovery.  
 
SECTION 2.24 LARGE SCALE PROTEIN PURIFICATION 
 Cell pellets obtained from Sections 2.20 or 2.21 were resuspended in 100-200 mL 
imidazole lysis buffer (2.6 mM NaH2PO4, 47.3 mM Na2HPO4, 500 mM NaCl, 10 mM 
imidazole, pH 8.0) with Complete protease inhibitor (Roche). Cells were lysed by 
sonication (Misonix sonicator 3000; power level 7, 30 s pulse, wait/delay 30 s, total time 
8 min with a microtip probe), and insoluble material was removed by centrifugation at 




pellets and added to 1-5 mL washed and equilibrated Ni2+-NTA agarose beads and left to 
incubate for 1 h at 4 ˚C with agitation in a glass column approximately I m long and 4 cm 
in diameter. After incubating, the Ni2+-NTA was allowed to settle and the remaining 
lysate was allowed to flow though the column. Ni2+-NTA agarose was washed with 
several volumes of imidazole wash buffer (2.6 mM NaH2PO4, 47.3 mM Na2HPO4, 500 
mM NaCl, 25 mM imidazole, pH 8.0). After the last of the wash buffer was drained, 
protein was eluted off of the Ni2+-NTA by adding 5 mL imidazole elution buffer (2.6 mM 
NaH2PO4, 47.3 mM Na2HPO4, 500 mM NaCl, 200mM imidazole, pH 8.0) and allowing 
it to flow through the resin and out of the column. A280 measurements were used to 
approximate eluted volume of protein by using the assumption that 1 absorption unit 
equals 1 mg/mL of protein and additional 5 mL elutions were performed until the A280 
readings dropped below 0.1. If eluted protein was to be further purified by FPLC it was 
concentrated in Amicon Ultra centrifugal filter tubes by centrifugation at 1,900 x g to a 
volume of 2 mL or less as required for application to the FPLC column. 
 
SECTION 2.25 PROTEIN MINIPREP 
Protein minipreps were performed according to verbal instructions from Dr. Omar 
Qazi, as described below. 
Overnight Express containing appropriate antibiotics was inoculated with the strain of 
interest and grown overnight at 37 ˚C with 250 rpm shaking. Cells were harvested by 




of 200 mM PMSF and 110 !L Cell Lytic reagent and left at room temperature to lyse 
for15-20 m with gentle rocking. 
100 !L of Ni2+-NTA agarose was prepared by washing with 1 mL lysis buffer. After 
addition of the lysis buffer the Ni2+-NTA agarose was allowed to settle and the 
supernatant was carefully pipeted off.  
The lysed cells were centrifuged at 20,800 x g for 10 min to pellet the insoluble 
material. The supernatant was pipeted off and added to the washed Ni2+-NTA agarose 
and incubated for 30-45 min at 4 ˚C with oscillation. After incubation, the Ni2+-NTA was 
allowed to settle and the supernatant was carefully pipeted off. Three washes with 1 mL 
imidazole wash buffer were then performed as in Section 2.23. After the last wash, bound 
species were eluted with 75 !L of imidazole elution buffer and the sample was 
centrifuged at 110 x g for 1 min to pellet the Ni2+-NTA. The eluted protein in the 
supernatant was removed by pipeting and saved. 
Protein minipreps were also done from 20 mL LB cultures induced with IPTG at an 
OD600 of 0.6 and grown for 2, 4, 6 h, or overnight post-induction.  
 
SECTION 2.26 DIALYSIS  
 Dialysis was performed using dialysis tubing (Section 2.1) with a 3,500 Da 
molecular mass cutoff. Tubing was washed in deionized water to remove storage buffer 
and rinsed in 1xHBS. One end of the tubing was securely closed using a dialysis clamp, 




was then securely closed with a second dialysis clamp. Samples were put in a 3-L beaker 
containing 2 L of 1xHBS with magnetic stirring for 1 h at 4 ˚C. After 1 h, samples were 
moved to 2 L of fresh 1xHBS and were left overnight with stirring at 4 ˚C. The next day, 
samples were carefully removed from the dialysis tubing by pipetting and frozen for 
long-term storage at $80 ˚C in small aliquots of 50-200 !L. 
 
SECTION 2.27 SIZE EXCLUSION CHROMATOGRAPHY PURIFICATION 
 All size exclusion chromatography (SEC) of recombinant proteins was carried out 
using a Hi-Load™ 16/60 Superdex™ 200 Prep Grade Column (GE Healthcare Bio-
Sciences AB, Uppsala Sweden, 10 - 600 kDa separation range for globular proteins) 
connected to an ÄKTA fast protein liquid chromatography (FPLC) system with fraction 
collector (GE Healthcare). All solutions and samples were stored at 4 ˚C and the FPLC 
system and fraction collector are enclosed in a refrigerator, maintained at 4 ˚C. The 
running buffer used was HBS with 150 mM NaCl and the SEC column was first 
equilibrated with 1 column volume (CV) of buffer at a flow rate of 0.5 to 1.0 mL/min. 
Between 1-2 mL of purified protein was loaded into a 2 ml loop and injected onto the 
SEC column after a 0.2 CV equilibration. The protein was eluted over 2 CVs at a flow 
rate of 1 mL/min and the fraction collector was set to collect 1-2 mL fractions. Fractions 
were assessed by SDS-PAGE to determine which peaks contained the protein of interest. 
Fractions found to contain the protein of interest were pooled, concentrated, and stored at 




 SEC column calibration was carried out by Dr. Qazi using low and high 
molecular weight calibration kits from GE Healthcare. 1.2 ml of a 1.0 mg ml-1 solution 
of blue dextran was loaded onto the SEC column at a flow rate of 1 mL/min in order to 
determine the void volume (V0) of the column. For molecular weight calibration a 
standard containing thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa), 
conalbumin (75 kDa), ovalbumin (44 kDa), carbonic anhydrase (29 kDa), ribonuclease A 
(13.7 kDa), and aprotinin (6.5 kDa) was made up in 1.5 ml of HBS and loaded. The UV 
absorption traces of the two standard runs were overlaid and the peak elution volumes 
determined. A graph of Log molecular weight against Kav was plotted where Kav = (VE- 
V0)/(VT-V0) and VE is the elution volume, V0 is the void volume and VT is the total 
column volume. This graph was used to determine the molecular weights of the unknown 
samples from the calculated Kav. 
SECTION 2.28 PROTEIN CONCENTRATION DETERMINATION 
 Protein concentration was determined by the BCA Protein Assay (Thermo 
Scientific Pierce, Rockford IL), according to the manufacturer’s specifications and read 
at A562. A standard curve was prepared using dilutions of Bovine Serum Albumin (BSA) 
included in the kit and a BSA standard curve with a linear regression was generated in 
Excel. Protein concentrations were calculated by inserting the A562 values for the protein 





SECTION 2.29 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS 
 Proteins were analyzed by SDS-PAGE using a Power Pac 300 (BioRad, Hercules, 
CA) and hand-poured gels.  
 85 mm x 75 mm x 1 mm protein gels were prepared by first polymerizing 5 mL of 
resolving gel [0.1% (w/v) sodium dodecyl sulfate (SDS), 12% (v/v) bis-acrylamide] in 
the presence of 0.06% (v/v) tetraethylmethyldiamide (TEMED) and 0.1% (w/v) 
ammonium persulfate (APS). A 2-mL stacking gel (0.1% (w/v) SDS, 5% (v/v) bis-
acrylamide) was polymerized atop the resolving gel in the presence of 0.01% (v/v) 
TEMED and 0.1% (w/v) APS. Protein samples were mixed 1 to 6 in a 5x concentrated 
protein sample buffer [125 mM Tris-HCL pH 6.8, 2% (w/v) SDS, 10% (v/v) %-
mercaptoethanol, 0.9% (w/v) bromophenol blue, 45% (v/v) glycerol] and boiled for 5 
min prior to loading. Crude samples were also centrifuged at 17,900 x g for 5 min before 
loading to pellet cell particles. Gels were electrophoresed using the Mini- PROTEAN® 
System (BioRad, Hercules, CA) at 180 V for 45-60 min in a Tris-Glycine buffer [25 mM 
Tris pH , 192 mM glycine, 0.1% (w/v) SDS]. For visualization of protein bands, gels 
were stained in 50% (w/v) Coomassie Brilliant Blue, 10% (v/v) acetic acid, and 45% 
methanol, destained in 10% acetic acid and 45% (v/v) methanol, and hydrated in 10% 
(v/v) glycerol. Gels were imaged using a scanner (Epson).  
 
SECTION 2.30 WESTERN BLOT 
 Western blots were routinely performed to verify that proteins carried a 6xHis tag. 




One of the two gels was stained in Coomassie as previously described (Section 2.29) and 
the other was prepared for Western blot by being soaked in transfer buffer (25 mM Tris 
pH, 192 mM glycine, 20% (v/v) methanol) along with pads and nitrocellulose membrane. 
Pads, membrane and gel were sandwiched inside a TransBlot SD Semi-Dry Transfer Cell 
(BioRad, Hercules, CA) and run at 13 V for 15 min. Transfer was monitored using a pre-
stained molecular weight standard. The nitrocellulose membrane was blocked in 50 mL 
of 2% (w/v) skimmed milk in PBT [0.5% (v/v) Tween in PBS] for 30 min with agitation 
at room temperature. The membrane was then washed in PBT and incubated with a 
mouse anti-polyhistidine monoclonal antibody (Sigma) diluted 1:2500 in PBT for 45 min 
with agitation at room temperature. After incubation with the antibody, the membrane 
was washed again with PBT and developed in a solution made with one tablet of 4-
chloro-1-naphthol dissolved in 10 mL of methanol and diluted to 50 mL in PBS with 
0.06% (v/v) Hydrogen Peroxide. Positive samples appear purple after developing. Blots 
were visually compared to Coomassie stained gels. 
 
SECTION 2.31 PIII-LOLC ELISA  
Purified LolC-t protein was added to different lanes of Nunc Maxisorp plates in 100 
!L volumes at variable concentrations. The plates were covered in plastic wrap and left 
overnight at 4 ˚C to allow binding. Plates were washed two times with PBS/0.05% Tween 
(PBS/T) and blocked by incubating plates at 25 ˚C for 1 h with 200 !L volumes of 3% 




protein was diluted to 50 !g/mL and 10 further doubling dilutions were also carried out. 
Dilutions were made in 3% milk-PBS/T and 100 !L of each dilution was added to the 
appropriate well for binding. The final column of wells on the plate contained only 
PBS/T as a negative control/reference. The plates were incubated at 25 ˚C for one h and 
washed three times as before. Streptavidin-Peroxidase Polymer was diluted 1 in 1,000 in 
PBS/T and added to microtiter plates in volumes of 100 mL per well. The plates were 
washed four times as previously described and 100 !L of TMB-Ultra was added to each 
well. The reaction was stopped after sufficient color development by the addition of 100 
!L of 2 M  H2SO4 to each well.  
 Elisa plates were read at 450 nm on a Tecan Infinite M200 plate reader. Each data 
point represents the mean of replicate absorbance values after reference subtraction. 
 This assay was also done with plates coated with heat-killed B. pseudomallei 
strain Bp82 at 1 OD/mL and detected with biotinylated pIII in the same fashion as above. 
Heat-killed Pseudomonas aeruginosa strain PAO1 was used as a negative control for 
binding. 
 
SECTION 2.32 MASS SPECTROMETRY 
 Mass spectrometry to determine molecular mass of purified proteins was 
performed in the ICMB Protein and Metabolite Analysis Facility at the University of 
Texas at Austin on a AB Sciex 4000 QTrap hybrid triple quadrupole-linear ion trap with 




SECTION 2.33 FLIC CLONING, EXPRESSION, AND PURIFICATION 
A genomic preparation of B. pseudomallei K96243 DNA (A gift from Dr. Alfredo 
Torres, UTMB, Galveston TX) was used as the template in the amplification of the 
nucleotides 495 $ 876 of the fliC gene, BPSL_3319, (corresponding to amino acid 
residues 166 $ 292 of the FliC protein) using two synthetic oligonucleotide primers. The 
primers OQ41 and OQ42 (A gift from Dr. Omar Qazi, UT Austin) were used (Table 2.2). 
The forward primer OQ41, incorporates a unique NcoI site, which results in the insertion 
of two additional amino acid residues, methionine and glycine, at the beginning of the 
truncated FliC-t protein. The reverse primer, OQ42, incorporates a unique NotI site after 
ATC, the last codon of the fliC-t intended sequence. PCR amplifications were performed 
using Roche High Fidelity Taq/Tgo polymerase with the addition of 20% Q-buffer at an 
annealing temperature of 62 ˚C and an extension time of 2.5 min  (Sections 2.1, 2.16). 
The resulting PCR product, a 423 bp fragment, was separated by electrophoresis on a 
0.8% agarose gel (Section 2.9) and purified by gel extraction (Section 2.10). This cleaned 
PCR product was then digested with NcoI and NotI (Section 2.12) and ligated (Section 
2.13) into the NcoI and NotI sites of the IPTG-inducible expression vector pET-28a(+) to 





Figure 2.3 Construct pET-28a(+)-KCMFLIC 
 
The ligation mixture was cleaned by PCR cleanup (Section 2.10) and transformed 
(Section 2.6) into electrocompetent E. coli DH5" cells (Section 2.3). Transformed cells 
were spread onto L-agar containing 50 !g/mL kanamycin and incubated at 37 ˚C. Single 
colonies were inoculated into 5 mL LB broth and grown overnight at 37 ˚C. Plasmids 
were then purified from the cells (Section 2.11) and submitted for sequencing (Section 
2.17). Sequence data was analyzed (Section 2.18) and found to be free of mutations. 
Construct pET-28a(+)-KCMFLIC was then transformed (Section 2.6) into E. coli 
BL21_Rosetta (DE3) cells (Section 2.3) and spread onto L-agar plates containing 50 
!g/mL kanamycin, creating strain KCM-Rosetta-FliC.  
 FliC-t protein was then expressed from strain KCM-Rosetta-FliC by growth in LB 
broth and induction with 1 mM IPTG at an OD600 of 0.6, followed by growth for 3.5 h at 




FliC-t protein as described in Section 2.23. Purified protein was analyzed by SDS PAGE 
on Coomassie-stained acrylamide gels (Section 2.29) and subjected to dialysis for buffer 
exchange (Section 2.26).  
 
SECTION 2.34 FLICR EXPRESSION AND PURIFICATION 
 Construct pET-15b-OQFLICR was obtained as a gift from Dr. Omar Qazi (UT 
Austin). This plasmid construct was transformed (Section 2.6) into E. coli strain BL21 
(DE3) (Section 2.3) and spread onto L-agar plates containing 100 !g/mL carbenicillin, 
creating strain KCM-DE3-FliCR.  
 FliCR-t protein was then expressed from strain KCM-DE3-FliCR by growth in 
OE at 37 ˚C overnight (Section 2.21). After growth, cultures were centrifuged to pellet 
the cells, and this cell pellet was used to purify FliCR-t protein as described in Section 
2.23. Eluted protein was further purified using size exclusion chromatography on the 
FPLC (Section 2.27), and FPLC calibration data was used to determine the size of the 
FliC-t protein. Purified protein was analyzed by SDS PAGE on Coomassie-stained 
acrylamide gels (Section 2.29) as well as by Western blot (Section 2.30) using a mouse 
anti-polyhistidine monoclonal antibody to recognize the polyhistidine tag on the FliCR-t 
protein.   
 
SECTION 2.35 PILA-T CLONING, EXPRESSION, AND PURIFICATION 




Torres, UTMB, Galveston TX) was used as the template in the amplification of the 
nucleotides 90-516 of the pilA gene, BPSL_0782, (corresponding to amino acid residues 
31-172 of the PilA protein) using two synthetic oligonucleotide primers. The primers KJ9 
and KJ11 were used (Table 2.2). Neither the forward primer, KJ9, nor the reverse primer, 
KJ11, incorporates extra DNA or amino acid residues to the construct, which ends with a 
TGA stop codon. PCR amplifications were performed using Roche High Fidelity 
Taq/Tgo polymerase with the addition of 20% Q-buffer and 5% DMSO at an annealing 
temperature of 59.4 ˚C and an extension time of 30 s (Sections 2.1, 2.16). The resulting 
PCR product, a 426 bp fragment, was separated by electrophoresis on a 0.8% agarose gel 
(Section 2.9) and purified by gel extraction (Section 2.10). This cleaned PCR product was 
ligated into the pEXP5-NT/TOPO vector (Section 2.14) to create plasmid pEXP5-
NT/TOPO-KCMPILA (Figure 2.4), which was then transformed into One Shot 
chemically competent E. coli cells by heat shock (Section 2.14). 
 
 




Transformed cells were spread onto L-agar containing 100 !g/mL ampicillin and 
incubated at 37 ˚C. Single colonies were inoculated into 5 mL LB broth and grown 
overnight at 37 ˚C. Plasmids were then purified from the cells (Section 2.11) and 
submitted for sequencing (Section 2.17). Sequence data was analyzed (Section 2.18) and 
found to be free of mutations. Construct pEXP5-NT/TOPO-KCMPILA was then 
transformed (Section 2.6) into E. coli BL21_Star™ (DE3) pLysS cells (Section 2.3) and 
spread onto L-agar containing 100 !g/mL ampicillin, creating strain KCM-pLysS-PilA.  
 PilA-t protein was then expressed from strain KCM-pLysS-PilA by growth in OE 
at 37 ˚C overnight (Section 2.21). After growth, cultures were centrifuged to pellet the 
cells, and this cell pellet was used to purify PilA-t protein as described in Section 2.23. 
Eluted protein was further purified using size exclusion chromatography on the FPLC 
(Section 2.27), and FPLC calibration data was used to determine the size of the PilA-t 
protein. Purified protein was analyzed by SDS PAGE on Coomassie-stained acrylamide 
gels (Section 2.29) as well as by Western blot (Section 2.30) using a mouse anti-
polyhistidine monoclonal antibody to recognize the polyhistidine tag on the PilA-t 
protein.   
 
SECTION 2.37 PIII-T CLONING, EXPRESSION, AND PURIFICATION  
 Phage M13K07 DNA, which contains the g3p gene, was used as the template in 
the amplification of the nucleotides 55-705 of the g3p gene (corresponding to the amino 




The primers, KCM17 and KCM18, were used (Table 2.2). The forward primer, KCM17, 
incorporates a unique NdeI site, which results in the insertion of 20 amino acid residues, 
including a 6x Histidine tag, at the beginning of the truncated pIII protein. The reverse 
primer, KCM18, adds a UGA stop codon and a unique XhoI site into the 3’ end of the 
cloned DNA sequence. PCR amplifications were performed using NEB Taq polymerase 
with provided 10x buffer with an annealing temperature of 58 ˚C and an extension time 
of 1 min (Sections 2.1, 2.16). The resulting PCR product, a 678 bp fragment, was 
separated by electrophoresis on a 0.8% agarose gel (Section 2.9) and purified by gel 
extraction (Section 2.10). This cleaned PCR product was then digested with NdeI and 
XhoI (section 2.12) and ligated (Section 2.13) into the IPTG-inducible expression vector 
pET-15b to create plasmid pET-15b-KCMPIII (Figure 2.5). 
 
 





 The ligation mixture was cleaned by PCR cleanup (Section 2.10) and transformed 
(Section 2.6) into electrocompetent E. coli DH5" cells (Section 2.3) and grown on L-agar 
plates containing 100 !g/mL of carbenicillin. Transformed cells were plated on L-agar 
containing 100 !g/mL carbenicillin and incubated at 37 ˚C. Single colonies were 
inoculated into 5 mL of LB broth and grown overnight at 37 ˚C. Plasmids were then 
purified from the cells (Section 2.11) and submitted for sequencing (Section 2.17). 
Sequence data was analyzed (Section 2.18) and found to be free of mutations. Construct 
pET-15b-KCMPIII was transformed (Section 2.6) into E. coli BL21_Rosetta (DE3) cells 
(Section 2.3) and spread onto L-agar plates containing 100 !g/mL carbenicillin, creating 
strain KCM-Rosetta-pIII. 
pIII-t protein was then expressed from strain KCM-Rosetta-pIII by growth in LB 
broth and induction with 0.1 mM IPTG at an OD600 of 0.6, followed by growth for 4 h at 
37 ˚C (Section 2.20). After growth, cultures were centrifuged to pellet the cells, and this 
cell pellet was used to purify pIII-t protein as described in Section 2.23. Eluted protein 
was further purified using size exclusion chromatography on the FPLC (Section 2.27), 
and FPLC calibration data was used to determine the size of the pIII-t protein. Purified 
protein was analyzed by SDS PAGE on Coomassie-stained acrylamide gels (Section 
2.29) as well as by Western blot (Section 2.30) using a mouse anti-polyhistidine 





SECTION 2.37 FIMA-T CLONING, EXPRESSION, AND PURIFICATION 
 Construct pET-15b-OQFIMA was obtained as a gift from Dr. Omar Qazi (UT 
Austin). This plasmid construct was transformed (Section 2.6) into E. coli strain 
BL21_Star™ (DE3) (Section 2.3) and spread onto L-agar plates containing 100 !g/mL 
carbenicillin, creating strain KCM-Star-FimA.  
 FimA-t protein was then expressed from strain KCM-Star-FimA by growth in OE 
at 37 ˚C overnight (Section 2.21). After growth, cultures were centrifuged to pellet the 
cells, and this cell pellet was used to purify FimA-t protein as described in Section 2.23. 
Eluted protein was further purified using size exclusion chromatography on the FPLC 
(Section 2.27), and FPLC calibration data was used to determine the size of the FimA-t 
protein. Purified protein was analyzed by SDS PAGE on Coomassie-stained acrylamide 
gels (Section 2.29) as well as by Western blot (Section 2.30) using a mouse anti-
polyhistidine monoclonal antibody to recognize the polyhistidine tag on the FimA-t 
protein.   
 
SECTION 2.38 LOLC-T EXPRESSION AND PURIFICATION 
 Construct pET-28a(+)-OQLOLCN was obtained as a gift from Dr. Omar Qazi 
(UT Austin). This plasmid construct was transformed (Section 2.6) into E. coli strain 
BL21_Rosetta (DE3) (Section 2.3) and spread onto L-agar plates containing 50 !g/mL 
kanamycin, creating strain KCM-Rosetta-LolC.  
 LolC-t protein was then expressed from strain KCM-Star-FimA by growth in LB 




18 ˚C (Section 2.20). After growth, cultures were centrifuged to pellet the cells, and this 
cell pellet was used to purify LolC-t protein as described in Section 2.24. Eluted protein 
was further purified using size exclusion chromatography on the FPLC (Section 2.27), 
and FPLC calibration data was used to determine the size of the LolC-t protein. Purified 
protein was analyzed by SDS PAGE on Coomassie-stained acrylamide gels (Section 
2.29) as well as by Western blot (Section 2.30) using a mouse anti-polyhistidine 
monoclonal antibody to recognize the polyhistidine tag on the LolC-t protein.   
 
SECTION 2.39 SODC-T CLONING, EXPRESSION, AND PURIFICATION 
 A genomic preparation of B. mallei 23344 DNA (A gift from Dr. Alfredo Torres, 
UTMB, Galveston TX) was used as the template in the amplification of the nucleotides 
102-237 of the sodC gene, BMA_0713, (corresponding to amino acid residues 35-179 of 
the SodC protein) using two synthetic oligonucleotide primers. The primers, OQ59 and 
OQ60 (a gift from Dr. Omar Qazi, UT Austin) were used (Table 2.2). The forward 
primer, OQ59, incorporates a unique NcoI site, which results in the insertion of two 
additional amino acid residues, methionine and glycine, at the beginning of the truncated 
SodC-t protein. The reverse primer, OQ60, incorporates a unique NotI site after CAA, the 
last codon of the fliC-t intended sequence. PCR amplifications were performed using 
Roche High Fidelity Taq/Tgo polymerase with the addition of 20% Q-buffer at an 
annealing temperature of 62 ˚C and an extension time of 2.5 min (Sections 2.1, 2.16). The 




agarose gel (Section 2.9) and purified by gel extraction (Section 2.10). This cleaned PCR 
product was then digested with NcoI and NotI (Section 2.12) and ligated (Section 2.13) 
into the NcoI and NotI sites of the IPTG-inducible expression vector pET-28a(+) to create 
plasmid pET-28a(+)-KCMSODC (Figure 2.6). 
 
 
Figure 2.6 Construct pET-28a(+)-KCMSODC 
 
The ligation mixture was cleaned by PCR cleanup (Section 2.10) and transformed 
(Section 2.6) into electrocompetent E. coli DH5" cells (Section 2.3). Transformed cells 
were spread onto L-agar containing 50 !g/mL kanamycin and incubated at 37 ˚C. Single 
colonies were inoculated into 5 mL LB broth and grown overnight at 37 ˚C. Plasmids 
were then purified from the cells (Section 2.11) and submitted for sequencing (Section 
2.17). Sequence data was analyzed (Section 2.18) and found to be free of mutations. 




BL21_Rosetta (DE3) cells (Section 2.3) and spread onto L-agar plates containing 50 
!g/mL kanamycin, creating strain KCM-Rosetta-SodC.  
SodC-t protein was then expressed from strain KCM-Rosetta-SodC by growth in LB 
broth and induction with 1 mM IPTG at an OD600 of 0.6, followed by growth for 3.5 h at 
37 ˚C (Section 2.20). Cells were centrifuged to pellet, and cell pellets were used to purify 
SodC-t protein as described in Section 2.23.  Purified protein was analyzed by SDS 
PAGE on Coomassie-stained acrylamide gels (Section 2.29) and subjected to buffer 
exchange by dialysis in 1x HBS (Section 2.26). 
 
SECTION 2.40 BOPA-T EXPRESSION AND PURIFICATION 
 BopA-t protein was expressed from strain OQ-Rosetta-BopA114 (a gift from Dr. 
Omar Qazi, Section 2.3) by growth in LB broth and induction with 1 mM IPTG at an 
OD600 of 0.6, followed by overnight growth for at 37 ˚C (Section 2.20). Cells were 
centrifuged to pellet, and cell pellets were used to purify BopA-t protein as described in 
Section 2.24. Purified protein was subjected to dialysis and analyzed by SDS PAGE on 
Coomassie-stained acrylamide gels (Section 2.29) and Western blot (Section 2.30) using 
a mouse anti-polyhistidine monoclonal antibody to recognize the polyhistidine on the 





SECTION 2.41 HEP-HAG PCR 
Section 2.41a BMA_A0810 
 A genomic preparation of B. mallei 23344 DNA (A gift from Dr. Alfredo Torres, 
UTMB, Galveston TX) was used as the template in the amplification of the nucleotides 
61-1158 of the BMA_A0810 gene (corresponding to amino acid residues 21-386 of the 
Hep Hag protein it encodes) using two synthetic oligonucleotide primers. The primers 
KJ1 and KJ2 were used (Table 2.2). The forward primer, KJ1, does not incorporate any 
additional nucleotides to the construct. The reverse primer, KJ2, incorporates a TAA stop 
codon after ACG, the last codon of the intended BMA_A0810 sequence. PCR 
amplifications were performed using Roche High Fidelity Taq/Tgo polymerase with the 
addition of 20% Q-buffer at an annealing temperature of 62 ˚C  + 0.3 ˚C per cycle and an 
extension time of 2.5 min (Sections 2.1, 2.16). The resulting PCR product, a 1095 bp 
fragment, was separated by electrophoresis on a 0.8% agarose gel (Section 2.9) and 
purified by gel extraction (Section 2.10). 
Section 2.41b BPSL_1705 
 A genomic preparation of B. pseudomallei K96243 DNA (A gift from Dr. Alfredo 
Torres, UTMB, Galveston TX) was used as the template in the amplification of the 
nucleotides 79-3603 of the BPSL_1705 gene (corresponding to amino acid residues 27-
1201 of the Hep Hag autotransporter protein it encodes) using two synthetic 
oligonucleotide primers. The primers KJ3 and KJ4 were used (Table 2.2). The forward 




primer, KJ4, incorporates a TAA stop codon after ACG, the last codon of the intended 
BPSL_1705 sequence. PCR amplifications were performed using Roche High Fidelity 
Taq/Tgo polymerase with the addition of 20% Q-buffer at an annealing temperature of 64 
˚C and an extension time of 1.5 min (Sections 2.1, 2.16). The resulting PCR product, a 
3525 bp fragment, was separated by electrophoresis on a 0.8% agarose gel (Section 2.9) 
and purified by gel extraction (Section 2.10).  
Section 2.41c  BTH_II0878 
 A genomic preparation of B. thailandensis E264 DNA (A gift from Dr. Annie 
Gnanam, UT Austin) was used as the template in the amplification of nucleotides 100-
1272 of the BTH_II0878 gene (corresponding to amino acid residues 34-424 of the 
HepHag protein it encodes) using two synthetic oligonucleotide primers. The primers 
KJ5 and KJ6 were used (Table 2.2). The forward primer, KJ5, does not incorporate any 
additional nucleotides to the construct. The reverse primer, KJ6, incorporates a TAA stop 
codon after CTC, the last codon of the intended BTH_II0878 sequence. PCR 
amplifications were performed using Roche High Fidelity Taq/Tgo polymerase with the 
addition of 20% Q-buffer at an annealing temperature of 50.8 ˚C and an extension time of 
1.5 min (Sections 2.1, 2.16). The resulting PCR product, a 1172 bp fragment, was 
separated by electrophoresis on a 0.8% agarose gel (Section 2.9) and purified by gel 





SECTION 2.42 TOLB PCR 
 A genomic preparation of B. mallei 23344 DNA (A gift from Dr. Alfredo Torres, 
UTMB, Galveston TX) was used as the template in the amplification of the nucleotides 
70-1290 of the tolB gene, BMA_2081 (corresponding to amino acid residues 24-430 of 
the TolB protein) using two synthetic oligonucleotide primers. The primers OQ95 and 
OQ96 were used (Table 2.2). The forward primer, OQ95, incorporates a unique NcoI site, 
which results in the insertion of two additional amino acid residues, methionine and 
glycine, at the beginning of the truncated TolB-t protein. The reverse primer, OQ96, 
incorporates a unique XhoI site after the last codon of the tolB-t intended sequence. PCR 
amplifications were performed using Roche High Fidelity Taq/Tgo polymerase with the 
addition of 20% Q-buffer at an annealing temperature of 62 ˚C and an extension time of 
2.5 min (Sections 2.1, 2.16). The resulting PCR product, a 1221 bp fragment, was 
separated by electrophoresis on a 0.8% agarose gel (Section 2.19) and purified by gel 






Chapter 3: Results 
 
SECTION 3.1  CLONING, EXPRESSION AND PURIFICATION RESULTS 
Section 3.1a FliC Cloning, Expression, and Purification Results 
 A truncated form of the B. pseudomallei fliC gene (fliC-t), BPSL_3319 (Section 
2.33) was PCR-amplified (Figure 3.1), cloned into the NcoI and NotI sites of the pET-
28a(+) vector, and transformed into E. coli DH5" cells. The resulting vector, pET-
28a(+)-KCMFLIC (Figure 2.3), was verified by DNA sequencing. 
 
 
Figure 3.1 PCR Amplification of fliC-t.  
Arrow at predicted size of DNA, 423 bp 
1.  PCR product of FliC-t.  
2. PCR product of FliC-t with 0.5% DMSO added 
 




pseudomallei BPSL_3319, FliC (FliC-t) were initially analyzed from purification of 
overnight culture in E. coli strain BL21_Rosetta (DE3) transformed with construct pET-
28a(+)-KCMFLIC grown in Overnight Express medium (OE) at either 37 ˚C or 18 ˚C. In 
this strategy, cells harvested were subjected to a protein miniprep (Section 2.25) and 
purified FliC-t protein was analyzed by SDS PAGE. The Coomassie-stained gel has 
strongly staining bands present in both the 37 ˚C and 18 ˚C samples at the predicted 
molecular mass of FliC-t, 13.9 kDa (Figure 3.2, at arrow). No Western blot was 




Figure 3.2: Protein Minipreps of FliC-t 
Arrow at predicted molecular mass of FliC-t, 13.9 kDa 
1. FliC-t grown in OE at 37 ˚C 





Section 3.1b  FliCR-t Expression and Purification 
 The levels of IPTG-induced overproduction of a second truncated recombinant B. 
pseudomallei BPSL_3319, FliC (FliCR-t) were initially analyzed from overnight cultures 
of E. coli strains BL21 (DE3), BL21_Star™ (DE3), BL21_Rosetta (DE3), and 
BL21_Star™ (DE3) pLysS transformed with construct pET-15b-OQFLICR (Figure 
2.2a), a gift from Dr. Omar Qazi) grown in OE. Cells were harvested and sonicated to 
obtain soluble and insoluble fractions, which were then analyzed by SDS PAGE. The 
Coomassie-stained acrylamide gel has a strongly staining band present in the soluble 
fraction at the predicted molecular mass of FliCR-t, 14.4 kDa in three of the four E. coli 
host strains: BL21 (DE3), BL21_Star™ (DE3), and BL21_Rosetta (DE3) (Figure 3.3, 
Lanes 1, 3, and 5, at the arrow).  
 
 
Figure 3.3: Initial Expression of FliCR-t in OE 
Arrow at predicted molecular mass of FliCR-t, 14.4 kDa1. DE3 Soluble   
2. DE3 Insoluble   
3. *DE3 Soluble   
4. *DE3 Insoluble   
5. Rosetta Soluble   
6. Rosetta Insoluble   
7. pLysS Soluble   





Strongly staining bands are also observed, likely at the predicted molecular mass of 
14.4 kDa in the insoluble fraction of these strains, however overloading of these samples 
on the gel led to aberrant running of the samples (Figure 3.3, Lanes 2, 4, and 6). No band 
at 14.4 kDa was observed in the soluble fraction of the BL21_Star™ (DE3) pLysS strain 
(Figure 3.3, Lane 7).  In addition, no band could be discerned in the insoluble fraction of 
this vector/host combination due to the presence of a large smear on the gel (Figure 3.3, 
Lane 8). No Western blot was performed of this expression gel (Figure 3.3), so the 
presence or absence of FliCR-t in these samples was not fully confirmed. Based on visual 
examination of the stained bands on the Coomassie-stained gel, the E. coli BL21 (DE3) 
host strain containing the pET-15b-OQFLICR construct, named KCM-DE3-FliCR, 
grown in OE was chosen for scaled up production of FliCR-t.  
FliCR-t was purified in a two-step process: first by affinity chromatography using 
Ni2+NTA agarose, and then by size-exclusion chromatography (sec) (Figure 3.4), and its 
size was determined by FPLC and mass-spectrometry (Appendix). The size of FliCR-t as 
determined by sec on the FPLC was calculated to be 22.1 kDa, which is quite a bit higher 
than the predicted molecular mass of FliCR-t, 14.4 kDa. This could be due to the shape of 
the protein. Calibration of the FPLC column was performed using globular proteins, and 
proteins that are not perfectly globular could run aberrantly in comparison. Mass 
spectrometry determined that the molecular mass of FliCR-t is 14.3 kDa, much closer to 
the predicted molecular mass of FliCR-t of 14.4 kDa. The small difference in molecular 






Figure 3.4: FPLC trace from FliCR-t Purification 
Material from peak 2 was used.  
1. 44.46 mL 
2. 93.56 mL 
 
Figure 3.5, a Coomassie-stained acrylamide gel, shows the optimized expression and 
purification of FliCR-t from strain KCM-DE3-FliCR. Production of FliCR-t is clearly 
induced using the OE (Figure 3.5, Lane 3, indicated by the arrow, compared to Lanes 1 
and 2). Lysis of the resulting pellet by sonication yields a strongly staining band 
corresponding to FliCR-t in the both the soluble and insoluble fractions (Figure 3.5, 
Lanes 4 and 5). The accompanying Western blot (Figure 3.6), using a mouse anti-
polyhistidine monoclonal antibody, again shows the presence of a strongly staining band 
near the 15-kDa molecular mass marker presumed to be FliCR-t. Purification of FliCR-t 
by affinity chromatography using NiNTA agarose removes all but a couple of the 
contaminating proteins from the suspension, leaving FliCR-t as the major species present 
(Figure 3.5, Lane 6). The Western blot confirms that these are contaminants, as the only 




band (Figure 3.6, lane 6). Purification of FliCR-t by sec on the FPLC removes the 
remaining contaminants, leaving FliCR-t as the homogenous species in the solution 





Figure 3.5: FliCR-t Expression and Purification Gel 
Arrow at predicted molecular mass of FliCR, 14.4 kDa 
1. BL21 (DE3) cell boilate, no vector 
2. BL21 (DE3) with pET-15b boilate  
3. KCM-DE3-FliCR boilate 
4. Soluble fraction from FliCR-t purification 
5. Insoluble fraction from FliCR-t purification 
6. NiNTA purified FliCR-t 
7. FPLC purified FliCR-t 
 
 
Figure 3.6: Western Blot of FliCR-t Expression and Purification 
Arrow at predicted molecular mass of FliCR, 14.4 kDa 
1. BL21 (DE3) cell boilate, no vector 
2. BL21 (DE3) cells with pET-15b boilate  
3. KCM-DE3-FliCR boilate 
4. Soluble fraction from FliCR-t purification 
5. Insoluble fraction from FliCR-t purification 
6. NiNTA purified FliCR-t 





Section 3.1c PilA-t Cloning, Expression, and Purification Results 
 A truncated form of the B. pseudomallei pilA gene (pilA-t), BPSL_0782 (Section 
2.35), was PCR-amplified, analyzed on an agarose gel (Figure 3.7), cloned into the 
pEXP5-NT/TOPO vector, and transformed into E. coli DH5" cells. The resulting vector, 
pEXP5-NT/TOPO-KCMPILA (Figure 2.4), was verified by DNA sequencing. 
 
 
Figure 3.7: PCR of pilA-t 
Arrow at predicted size of pilA-t, 426 bp 
1. With 5% DMSO 
2. With 10% DMSO 
 
 The levels of IPTG-induced overproduction of the recombinant B. pseudomallei 
BPSL_0782, PilA (PilA-t), were initially analyzed from an overnight culture of E. coli 
BL21_ Rosetta (DE3) cells transformed with pEXP5-NT/TOPO-KCMPILA (Figure 2.4) 
grown in OE media. After a protein miniprep (Section 2.25), crude cell boilates and 




molecular mass of 16.5 kDa of the expressed construct was visible in the purified sample 
on the Coomassie-stained gel (Figure 3.8, Lane 2). This may be due to under-loading of 
the gel lane, low protein concentrations, and/or absence of PilA-t after purification due to 
it not being eluted from the NiNTA agarose properly. The Coomassie-stained gel did 
have a band in the boilate sample, indicated by the arrow in Figure 3.8 estimated to near 
the 15 kDa molecular mass marker band, which could be PilA-t.   
 
 
Figure 3.8: Expression and Purification in BL21_Rosetta (DE3) 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. Crude cell boilate 
2. Protein miniprep  
 
 
 The pEXP5-NT/TOPO-KCMPILA construct was then transformed into three 
additional E. coli expression strains, BL21 (DE3), BL21_Star™ (DE3), and BL21_Star™ 
(DE3) pLysS, and also re-transformed into BL21_Rosetta (DE3) competent cells. These 




with 1.0 mM IPTG at an OD600 of 0.6 in LB broth and then grown for 3.5 h at 37 ˚C. 
Whole cell boilates obtained from each of these expression conditions were analyzed by 
SDS PAGE, but interpretation of the Coomassie-stained gel was inconclusive due to 
over-loading (Figure 3.9).  
 
Figure 3.9: Expression in four E. coli strains in LB with 1 mM IPTG induction and OE. 
Crude cell boilates. 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21 (DE3), LB 
2. BL21 (DE3), OE 
3. BL21_Star™ (DE3) pLysS, LB 
4. BL21_Star™ (DE3) pLysS, OE 
5. BL21_Rosetta (DE3), LB  
6. BL21_Rosetta (DE3), OE 
7. BL21_Star™ (DE3), LB 
8. BL21_Star™ (DE3), OE 
 
 Although the SDS PAGE analysis could have been repeated with reduced sample 
protein concentrations, expression was instead re-evaluated systematically in LB broth, 
inducing with 0.1 and 1.0 mM IPTG at an OD600 of 0.6. Whole cell boilates (Section 
2.22) were made of samples taken post-induction at 2, 4, 6 h and overnight and analyzed 
by SDS PAGE using Coomassie-stained acrylamide gels (Figures 3.10, 3.11, 3.12, and 







Figure 3.10: PilA-t Expression in BL21 
(DE3), LB broth.  
 
 
Figure 3.11: PilA-t expression in 






Figure 3.12: PilA-t expression in 
BL21_Rosetta (DE3), LB 
broth. 
 
Figure 3.13: PilA-t expression in 
BL21_Star™ (DE3) pLysS, 
LB broth.  
Lane key for Figures 3.10-3.13 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
Crude cell boilates. 
1. 0.1 mM IPTG induction, 2 h growth 
2. 0.1 mM IPTG induction, 4 h growth 
3. 0.1 mM IPTG induction, 6 h growth 
4. 0.1 mM IPTG induction, overnight growth 
5. 1.0 mM IPTG induction, 2 h growth 
6. 1.0 mM IPTG induction, 4 h growth 
7. 1.0 mM IPTG induction, 6 h growth 




marker band, below the predicted 16.5-kDa molecular mass of PilA-t, using the
E. coli expression host strains BL21_Star™ (DE3) (Figure 3.11) and BL21_Star™ (DE3) 
pLysS (Figure 3.13). Strongly staining bands were not seen near 15 or 16.5 kDa using the 
E. coli expression host strains BL21 (DE3) or BL21_Rosetta (DE3) (Figures 3.10 and 
3.12). Western blots were not performed of these gels, so no definitive conclusions as to 
the presence or absence of PilA-t in these samples can be made. Based upon the SDS 
PAGE analysis above, however, PilA-t appeared to be present at substantial levels in the 
following three samples all transformed with pEXP5-NT/TOPO-KCMPILA: 
BL21_Star™ (DE3) induced with 1.0 mM IPTG at an OD600 of 0.6 and grown for 2 h 
post-induction, BL21_Star™ (DE3) pLysS induced with 0.1 mM IPTG at an OD600 of 0.6 
and grown for 4 h post-induction, and BL21_Star™ (DE3) pLysS induced with 1.0 mM 
IPTG at an OD600 of 0.6 and grown for 4 h post-induction. These three boilates were 
analyzed by SDS PAGE (Figure 3.14) and Western blot (Figure 3.15) using an mouse 
anti-polyhistidine monoclonal antibody (Section 2.30). Moderately staining bands were 
seen on the gel for all three samples near the 15 kDa molecular mass marker band but 
below the predicted 16.5 kDa molecular mass of PilA-t (Figure 3.14). Weak bands on the 
nitrocellulose blot membrane (Figure 3.15) were also observed near the 15-kDa 






Figure 3.14: Gel of Promising Expression Conditions in LB broth. Crude cell boilates. 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3) with 1.0 mM IPTG induction and 2 h growth 
2. BL21_Star™ (DE3) pLysS with 0.1 mM IPTG induction and 4 h growth 
3. BL21_Star™ (DE3) pLysS with 1.0 mM IPTG induction and 4 h growth 
 
 
Figure 3.15: Western blot of Promising Expression Conditions in LB broth. Crude cell 
boilates. 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3) with 1.0 mM IPTG induction and 2 h growth 
2. BL21_Star™ (DE3) pLysS with 0.1 mM IPTG induction and 4 h growth 




The solubility of PilA-t was assessed using the three different expression conditions 
identified in the paragraph above. Cells were lysed by sonication (Section 2.24) and the 
soluble and insoluble fractions were analyzed by SDS PAGE using a Coomassie-stained 
acrylamide gel (Figure 3.16). Strongly staining bands migrating near the 15-kDa 
molecular mass marker indicated that large amounts of protein appeared to be in the 
insoluble fraction of the BL21_Star™ (DE3) strain expression (Figure 3.16, Lane 2). 
Weakly staining bands migrating near the 15-kDa molecular mass marker were present in 
the soluble fractions for all of the conditions analyzed on this gel (Figure 3.16, Lanes 1, 
3, and 5). 
 
Figure 3.16: Solubility of promising PilA-t Expression Conditions in LB Broth 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3) with 1.0 mM IPTG induction and 2 h growth, Soluble 
2. BL21_Star™ (DE3) with 1.0 mM IPTG induction and 2 h growth, Insoluble 
3. BL21_Star™ (DE3) pLysS with 0.1 mM IPTG induction and 4 h growth, Soluble 
4. BL21_Star™ (DE3) pLysS with 0.1 mM IPTG induction and 4 h growth, Insoluble 
5. BL21_Star™ (DE3) pLysS with 1.0 mM IPTG induction and 4 h growth, Soluble 





BL21_Star™ (DE3) and BL21_Star™ (DE3) pLysS transformed with pEXP5-
NT/TOPO-KCMPILA were then grown in OE at 37 ˚C overnight in order to explore 
whether higher levels of soluble PilA-t could be obtained. These cells were lysed by 
sonication (Section 2.24) to separate soluble and insoluble components and analyzed by 
SDS PAGE on a Coomassie-stained acrylamide gel. Strongly staining bands were 
observed at near the 15-kDa molecular mass marker in the insoluble fractions of the 
sample from both bacterial strains (Figure 3.17, Lanes 2 and 4). A weakly staining band 
of soluble protein near the 15 kDa molecular mass marker was observed in the 
BL21_Star™ (DE3) pLysS sample (Figure 3.17, Lane 3) but not visibly observed in the 
BL21_Star™ (DE3) sample (Figure 3.17, Lane 1), possibly due to underloading of the 
acrylamide gel. No Western blot was done with this gel, so it is not possible to determine 
the presence or absence of soluble PilA-t in BL21_Star™ (DE3) cells. The E. coli 
BL21_Star™ (DE3) pLysS strain containing the pEXP5-NT/TOPO-KCMPILA 







Figure 3.17: Solubility of PilA-t in OE 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3), Soluble 
2. BL21_Star™ (DE3), Insoluble 
3. BL21_Star™ (DE3) pLysS, Soluble 
4. BL21_Star™ (DE3) pLysS, Insoluble 
 
PilA-t was purified in a two-step process: first by affinity chromatography using 
NiNTA agarose, and then by size-exclusion chromatography (sec) (Figure 3.18), and its 
size was calculated by FPLC and confirmed with mass spectrometry. The size of PilA-t 
as calculated by FPLC using a calibrated column is 22.2 kDa, which is quite a bit higher 
than the predicted molecular mass of PilA-t, 16.5 kDa. This could be due to the shape of 
the protein. Calibration of the FPLC column was performed using globular proteins, and 
proteins that are not perfectly globular could run aberrantly in comparison. Mass 
spectrometry determined the molecular mass of PilA-t to be 16.4 kDa, which is very 




molecular mass between predicted and actual could be due to the loss of the initial 
methionine of the protein. 
 
Figure 3.18: Representative FPLC trace from PilA-t purification 
Material from peak 5 was collected. 
1. 45.28 mL 
2. 57.19 mL 
3. 72.69 mL 
4. 89.65 mL 
5. 94.47 mL 
 
Figure 3.19 shows the optimized expression and purification conditions used for the 
production of PilA-t from strain KCM-pLysS-PilA. Production of PilA-t is clearly 
induced using the OE (Figure 3.19, Lane 2, indicated by the arrow, compared to Lane 1). 
Lysis of the resulting cell pellet by sonication yields a weakly staining band 
corresponding to PilA-t (Figure 3.19, Lane 3) compared to the insoluble portion (Figure 
3.19, Lane 4). The accompanying Western blot (Figure 3.20), using a mouse anti-




near the 15 kDa molecular mass marker presumed to be PilA-t. The Western blot of the 
whole cell boilate and the insoluble pellet (Figure 3.20, Lanes 2 and 4) also shows the 
presence of some aggregates that are not present in the soluble fraction (Figure 3.20, 
Lane 3). Purification of PilA-t by affinity chromatography using NiNTA agarose removes 
all but a couple of the contaminating proteins from the suspension, leaving PilA-t as the 
major species present (Figure 3.19, Lane 5). The Western blot confirms that these are 
contaminants, as the only band present on the blot corresponds to PilA-t near the 15-kDa 
molecular mass marker band (Figure 3.20, lane 5). Purification of PilA-t by sec on the 
FPLC removes the remaining contaminants, leaving PilA-t as the homogenous species in 
the solution (Figures 3.19 and 3.20, Lane 6).  
 
Figure 3.19: Gel of Expression and Purification in BL21_Star™ (DE3) pLysS in OE 
Broth 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3) pLysS with no 
plasmid vector, Crude cell boilate 
2. BL21_Star™ (DE3) pLysS expression 
cell pellet, crude cell boilate 
3. Purification soluble fraction 
4. Purification insoluble pellet 
5. Ni2+-NTA purified PilA-t 






Figure 3.20: Western Blot of Expression and Purification in BL21_Star™ (DE3) pLysS 
in OE Broth 
Arrow at predicted molecular mass of PilA-t, 16.5 kDa 
1. BL21_Star™ (DE3) pLysS with no 
plasmid vector, Crude cell boilate 
2. BL21_Star™ (DE3) pLysS expression 
cell pellet, crude cell boilate 
3. Purification soluble fraction 
4. Purification insoluble pellet 
5. Ni2+-NTA purified PilA-t 
6. FPLC purified PilA-t 
 
Section 3.1d pIII Cloning, Expression, and Purification Results 
 Previously, during rounds of phage panning in phage display against LolC-t 
protein, it was noticed that the M13K07 phage had a strong affinity for LolC-t protein 
(Dr. Mridula Rani, personal communication). It was believed that this interaction was 
between the pIII protein of the phage and the LolC-t protein (Dr. George Giorgiou, 
personal communication). If the pIII protein actually binds to LolC-t, this interaction 
could be exploited in our favor in order to use pIII protein as a detection reagent for 
pathogenic Burkholderia species. To this end, the pIII protein was cloned, expressed, and 
purified. 




amplified and analyzed on an agarose gel (Figure 3.21), cloned into the pET-15b vector, 
and transformed into E. coli DH5" cells. The resulting vector, pET-15b-KCMPIII (Figure 
2.5), was verified by DNA sequencing.  
 
Figure 3.21: PCR of g3p-t DNA with different annealing temperatures 
Arrow at predicted size of g3p-t DNA, 651 bp 
1. 58.0 ˚C 
2. 58.5 ˚C 
3. 59.5 ˚C 
4. 60.8 ˚C 
5. 62.4 ˚C 
6. 63.6 ˚C 
7. 64.5 ˚C 
8. 65.0 ˚ 
 
The levels of IPTG-induced overproduction of a truncated recombinant form of the 
phage M13K07 pIII protein (pIII-t) were initially analyzed using E. coli strains BL21 
(DE3), BL21_Star™ (DE3), BL21 Rosetta (DE3), and BL21_Star™ (DE3) pLysS 
transformed with construct pET-15b-KCMPIII (Figure 2.5). These transformed strains 
were grown in LB broth and induced with either 1.0 or 0.1 mM IPTG at an OD600 of 0.6. 
Samples were taken at 2, 4, 6 h, and overnight for cultures grown at 37 ˚C post-induction; 




were analyzed by SDS PAGE using Coomassie-stained acrylamide gels. Weakly staining 
bands, consistent with the predicted molecular mass of 25.8 kDa, appear in all of the gels 
(Figures 3.22 through 3.29). In addition, all of the samples contained a strongly staining 
band at approximately 36 kDa (Figures 3.22 through 3.29, indicated by the arrow), which 
is considerably higher than the predicted molecular mass of the pIII-t protein. From these 
gels it appears that induction with 0.1 mM IPTG at an OD600 of 0.6 and protein 
expression for 4 h post-induction may be sufficient for overproduction of pIII-t in any of 
the four transformed strains studied. 
 
Lane key for Figures 3.22-3.29 
Arrow at presumptive pIII-t. 
1. 37 ˚C, 2 h post-induction 
2. 37 ˚C, 4 h post-induction 
3. 37 ˚C, 6 h post-induction 
4. 37 ˚C, overnight post-induction 
5. 18 ˚C, 6 h post-induction 




Figure 3.22: Expression of pIII-t in E. 
coli BL21 (DE3) with 0.1 
mM IPTG induction 
 
Figure 3.23: Expression of pIII-t in E. 
coli BL21 (DE3) with 1 






Figure 3.24: Expression of pIII-t in E. 
coli BL21_Star™ (DE3), 
0.1 mM IPTG induction 
 
Figure 3.25: Expression of pIII-t in E. 
coli BL21_Star™ (DE3) 
with 1 mM IPTG induction 
 
 
Figure 3.26: Expression of pIII-t in E. 
coli BL21_Rosetta (DE3), 
0.1 mM IPTG induction 
 
Figure 3.27: Expression of pIII-t in E. 
coli BL21_Rosetta (DE3) 
with 1 mM IPTG induction 
 
Figure 3.28: Expression of pIII-t in E. 
coli BL21_Star™ (DE3) 
pLysS, 0.1 mM IPTG  
 
 
Figure 3.29: Expression of pIII-t in E. 
coli BL21_Star™ (DE3) 






The four transformed BL21 strains listed above were then assessed for their ability to 
express soluble pIII-t. Cells were grown in LB broth, induced with 0.1 mM IPTG at an 
OD600 of 0.6, and grown for 4 h post-induction. Harvested cell pellets were lysed by 
sonication to separate the soluble and insoluble cellular components. The soluble and 
insoluble fractions were then analyzed by SDS PAGE using Coomassie-stained 
acrylamide gels (Figure 3.30). A Western blot was also performed with a mouse anti-
polyhistidine monoclonal antibody in order to determine the presence or absence of pIII-t 
(Figure 3.31). All four transformed cell types showed strongly staining bands in the 
insoluble portion of the sample migrating at approximately 36 kDa (Figure 3.31, 
indicated by arrow). Each strain also had a smaller band in the soluble fraction also 
migrating at approximately 36 kDa (Figure 3.30). The same 36-kDa bands stain strongly 
on the Western blot nitrocellulose membrane, indicative of the presence of pIII-t (Figure 
3.31). The pIII-t truncated protein contains 3 disulfide bridges formed between 6 
cysteines, and the aberrant migration of this protein at 36 kDa instead of 25.8 kDa could 
be due to disulfide bonds in the truncated protein that are either re-formed or not fully 






Figure 3.30: Soluble vs. Insoluble expression gel of pIII-t with 0.1 mM IPTG induction 
Arrow at presumptive pIII-t 
1. BL21 (DE3) soluble 
2. BL21 (DE3) insoluble 
3. BL21_Star™ (DE3) soluble 
4. BL21_Star™ (DE3) insoluble 
5. BL21_Rosetta (DE3) soluble 
6. BL21_Rosetta (DE3) insoluble 
7. BL21_Star™ (DE3) pLysS soluble 




Figure 3.31: Soluble vs. Insoluble Western blot of pIII-t expression with 0.1 mM IPTG 
induction 
Arrow at presumptive pIII-t. 
1. BL21 (DE3) soluble 
2. BL21 (DE3) insoluble 
3. BL21_Star™ (DE3) soluble 
4. BL21_Star™ (DE3) insoluble 
5. BL21_Rosetta (DE3) soluble 
6. BL21_Rosetta (DE3) insoluble 
7. BL21_Star™ (DE3) pLysS soluble 






 Based upon the SDS PAGE and Western blot analyses, the E. coli BL21_Rosetta 
(DE3) host strain transformed with pET-15b-KCMPIII, named KCM-Rosetta-pIII, was 
used for scale-up of protein overproduction.  
pIII-t was purified in a two-step process: first by affinity chromatography using 
NiNTA agarose, and then by size-exclusion chromatography (sec) (Figure 3.32), and its 
size was calculated by FPLC and confirmed with mass spectrometry (Appendix). The 
size of pIII-t as calculated by FPLC using a calibrated column is 31.2 kDa, which is quite 
a bit higher than the predicted molecular mass of pIII-t, 25.8 kDa. This could be due to 
the shape of the protein. Calibration of the FPLC column was performed using globular 
proteins, and proteins that are not perfectly globular could run aberrantly in comparison. 
Mass spectrometry determined the molecular mass of pIII-t to be 25.8 kDa, which is 
identical to the predicted molecular mass of 25.8 kDa. 
 
Figure 3.32: Representative FPLC trace from pIII-t purification 
Material from peak 4 collected 
1. 44.56 mL 
2. 63.11 mL 
3. 80.73 mL 




Section 3.1e FimA-t Expression and Purification Results  
 The levels of IPTG-induced overproduction of a second truncated recombinant B. 
pseudomallei BPSL_1801, FimA (FimA-t) were initially analyzed from overnight 
cultures of E. coli strains BL21 (DE3), BL21_Star™ (DE3), BL21_Rosetta (DE3), and 
BL21_Star™ (DE3) pLysS transformed with construct pET-15b-OQFIMA (Figure 2.2b, 
a gift from Dr. Omar Qazi) grown in OE. Cells were harvested and sonicated to obtain 
soluble and insoluble fractions, which were then analyzed by SDS PAGE. The 
Coomassie-stained acrylamide gel showed strongly staining bands present in the soluble 
fractions approximately at the predicted molecular mass of FimA-t of 17.6 kDa, in all of 
the four E. coli host strains: BL21 (DE3), BL21_Star™ (DE3), BL21_Rosetta (DE3), and 
BL21_Star™ (DE3) pLysS (Figure 3.33, Lanes 1, 3, 5, and 7, indicated by the arrow).  
 
Figure 3.33: FimA Expression in OE Media Gel 
Arrow at predicted FimA-t molecular mass, 17.6 kDa 
1. DE3 Soluble 
2. DE3 Insoluble 
3. *DE3 Soluble 
4. *DE3 Insoluble 
5. Rosetta Soluble 
6. Rosetta Insoluble 
7. pLysS Soluble 
8. pLysS Insoluble 
 




17.6 kDa in the insoluble fraction from these host strains, however overloading of these 
samples on the gel led to aberrant running of the samples (Figure 3.33, Lanes 2, 4, 6, and 
8).  No Western blot was performed of this expression gel, so the presence or absence of 
FimA-t in these samples was not fully confirmed. Based on visual examination of the 
stained bands on the Coomassie-stained gel, the E. coli BL21_Star™ (DE3) strain 
containing the pET-15b-OQFIMA construct, named KCM-Star-FimA, grown in OE was 
chosen for scaled up production of FimA-t. 
FimA-t was purified in a two-step process: first by affinity chromatography using 
NiNTA agarose, and then by size-exclusion chromatography (sec) (Figure 3.34), and its 
size was calculated by FPLC. The size of FimA-t as calculated by FPLC using a 
calibrated column is 22.4 kDa, which is quite a bit higher than the predicted molecular 
mass of FimA-t, 17.6 kDa. This could be due to the shape of the protein. Calibration of 
the FPLC column was performed using globular proteins, and proteins that are not 






Figure 3.34: FPLC trace from FimA-t Purification 
Material collected from peak 5 was used. 
1. 15.93 mL 
2. 44.91 mL 
3. 67.45 mL 
4. 84.71 mL 
5. 93.88 mL 
 
Figure 3.35 shows the optimized expression and purification conditions used for the 
production of FimA-t from strain KCM-Star-FimA. Production of FimA-t is clearly 
induced using OE (Figure 3.35, Lane 3, indicated by the arrow, compared to Lanes 1 and 
2). Lysis of the resulting cell pellet by sonication yields a strongly staining band 
corresponding to FimA-t (Figure 3.35, Lane 4) is present in both the soluble and 
insoluble fractions. The accompanying Western blot (Figure 3.36), using a mouse anti-
polyhistidine monoclonal antibody, again shows the presence of a strongly staining band 
in each sample near the 15-kDa molecular mass marker presumed to be FimA-t. The 
Western blot of the whole cell boilate and the insoluble pellet (Figure 3.36, Lanes 3 and 
5) also shows the presence of some aggregates that are not present in the soluble fraction 
(Figure 3.20, Lane 3).  Purification of FimA-t by affinity chromatography removes all but 




(Figure 3.35, Lane 6). The Western blot confirms most of these other bands to be 
contaminants, but there is some degradation of the FimA-t protein, likely at the C-
terminus, that shows up as a couple of bands smaller than the main, strongly staining 
band of FimA-t near 15-kDa. Purification of FimA-t by sec on the FPLC removes some 
of the contaminants, but a high molecular mass contaminant near 75 kDa still remains in 
the sample (Figure 3.35, Lane 7). Absence of the 75-kDa band on the Western blot 
confirms this to be a contaminant and not a multimerized form of FimA-t (Figure 3.36, 






Figure 3.35: FimA Expression and Purification Gel 
Arrow at predicted FimA-t molecular mass, 17.6 kDa 
1. BL21_Star™ (DE3) boilate, no vector 
2. BL21_Star™ (DE3), pET-15b boilate 
3. KCM-Star-FimA boilate 
4. Soluble fraction from FimA-t 
purification 
5. Insoluble pellet from FimA-t 
purification 
6. NiNTA purified FimA-t 
7. FPLC purified FimA-t 
 
 
Figure 3.36: Western Blot of FimA Expression and Purification 
Arrow at predicted FimA-t molecular mass, 17.6 kDa 
1. BL21_Star™ (DE3) boilate, no vector 
2. BL21_Star™ (DE3), pET-15b boilate 
3. KCM-Star-FimA boilate 
4. Soluble fraction from FimA-t 
purification 
5. Insoluble pellet from FimA-t 
purification 
6. NiNTA purified FimA-t 





Section 3.1f LolC Expression and Purification 
 The levels of IPTG-induced overproduction of the recombinant predicted 
periplasmic domain of B. pseudomallei BPSL_2277, LolC (LolC-t) were initially 
analyzed in the E. coli BL21_Rosetta (DE3) strain transformed with pET-28a(+)-
OQLOLCN (Figure 2.2c, a gift from Dr. Omar Qazi) using a purification-based analysis. 
This new strain, KCM-Rosetta-LolC, was grown in OE at 37 ˚C as previously reported 
(32). After a protein miniprep small-scale purification (Section 2.25), the purified soluble 
protein was analyzed by SDS PAGE using a Coomassie-stained acrylamide gel and a 
weakly staining band was observed near the LolC-t predicted molecular mass of 26.3 kDa 
(Figure 3.37, at the arrow) (Consistent with (Whitlock et al. 2010).  
 
Figure 3.37: Purification of LolC-t in OE  
Arrow at predicted molecular mass of LolC-t, 26.3 kDa 
Lane 1: LolC-t protein miniprep from E. coli BL21_Rosetta (DE3)  
 




construct pET-28a(+)-OQLOLCN were then grown in OE at 18 ˚C (Section 2.21). After 
a protein miniprep (Section 2.25), the purified soluble protein was analyzed by SDS 
PAGE and Western blot with a mouse anti-polyhistidine monoclonal antibody alongside 
a sample grown in OE at 37 ˚C. A thick, strongly staining band was observed on the 
Coomassie-stained gel near 26.3 kDa, the predicted molecular mass of LolC-t, in the 18 
˚C sample, and a weakly staining band of the same size was observed in the 37 ˚C 
sample, as seen previously (Figure 3.38 at arrow). The Western blot suggests that the 
band near 26.3 kDa is LolC-t (Figure 3.39 at arrow). A second band also appears in the 
LolC-t sample grown at 18 ˚C in the Western blot, which appears to be a stable truncated 







Figure 3.38: Gel comparison of LolC-t 
in 37 ˚C and 18 ˚C in 
BL21_Rosetta (DE3) 
Arrow at predicted molecular mass of 
LolC-t, 26.3 kDa 
1: LolC-t protein miniprep 37 ˚C 
2: LolC-t protein miniprep 18 ˚C 
 
Figure 3.39: Western blot comparison of 
LolC-t in 37 ˚C and 18 ˚C 
in BL21_Rosetta (DE3) 
Arrow at predicted molecular mass of 
LolC-t, 26.3 kDa 
1: LolC-t protein miniprep 37 ˚C 
2: LolC-t protein miniprep 18 ˚C 
 
 
 To further optimize expression via purification, LolC-t was then expressed in strain 
KCM-Rosetta-LolC using LB broth and 1.0 mM IPTG induction at an OD600 of 0.6. 
Cultures were moved to 18 ˚C post-induction and grown overnight for 16 h. Protein 
purification was performed, (Section 2.23) and the purified protein elution fractions were 
analyzed by SDS PAGE using a Coomassie-stained acrylamide gel. Strongly staining 
bands were seen in all of the eluted LolC-t fractions near 26.3 kDa (Figure 3.40, at the 
arrow), consistent with the previous Western blot for LolC-t. Scaled-up expression and 




broth with 1.0 mM IPTG induction at an OD600 of 0.6 and grown for 16 h post-induction 
at 18 ˚C.  
 
Figure 3.40: NiNTA-purified LolC-t eluted fractions from LB growth at 18 ˚C post-
induction 
Arrow at predicted molecular mass of LolC-t, 26.3 kDa 
Lane 1-5: Eluted fractions 1-5 
 
Purification of LolC-t was performed in a two-step process: first by affinity 
chromatography using NiNTA agarose, and then by size-exclusion chromatography (sec) 
(Figure 3.41), and its size was calculated by FPLC and measured by mass spectrometry 
(Appendix). The size of LolC-t as calculated by FPLC using a calibrated column is 34.6 
kDa, which is quite a bit higher than the predicted molecular mass of LolC-t, 26.3 kDa. 
This could be due to the shape of the protein. Calibration of the FPLC column was 




aberrantly in comparison. Mass spectrometry determined the mass of LolC-t to be 26.3 
kDa, which is identical to the predicted molecular mass of 26.3 kDa. 
 
Figure 3.41: Representative FPLC trace from LolC-t Purification 
Material from peak 4 was collected. 
1. 45.39 mL 
2. 56.88 mL 
3. 71.74 mL 
4. 88.15 mL 
 
Section 3.1g  BopA-t Expression and Purification Results  
 BopA-t was expressed and purified as described in Section 2.40 and the affinity-
purified protein was analyzed by SDS PAGE (Figure 3.42) and Western blot (Figure 
3.43) using a mouse anti-polyhistidine monoclonal antibody. As apparent in the gel and 
Western images, BopA is an incredibly labile protein, prone to degradation during 
purification. Most of the bands present on the gel (Figure 3.42), even those that are not 
found on the Western blot (Figure 3.43), are likely degraded products of BopA, and could 
have lost part or all of their polyhistidine tag. Full-length BopA-t, as indicated by the 




expression and purification protocols (Dr. Omar Qazi, personal communication).  
 
Figure 3.42: Gel of affinity purified 
BopA-t 
Arrow at the predicted molecular mass 
of BopA-t, 54.7 kDa 
1. 2.5 mg total protein loaded 
2. 5 mg total protein loaded 
 
 
Figure 3.43: Western blot of affinity 
purified BopA-t 
Arrow at the predicted molecular mass 
of BopA-t, 54.7 kDa 
1. 2.5 mg total protein loaded 
2. 5 mg total protein loaded
Section 3.1h SodC Cloning, Expression and Purification Results 
 A truncated form of B. mallei sodC gene (sodC-t), BMA_0713 (Section 2.39), 
was PCR-amplified (Figure 3.44), cloned into the NcoI and NotI sites of the pET-28a(+) 
vector, and transformed into E. coli DH5" cells. The resulting vector, pET-28a(+)-






Figure 3.44: PCR of the sodC-t gene 
Arrow at predicted size of sodC-t DNA, 477 bp 
1. Regular PCR conditions 
2.  With added 0.5% DMSO 
 
The levels of IPTG-induced overproduction of a truncated recombinant B. mallei 
BMA_0713, SodC (SodC-t) were initially analyzed from purification of overnight culture 
in E. coli strain BL21_Rosetta (DE3) transformed with construct pET-28a(+)-
KCMSODC (new strain KCM-Rosetta-SodC) grown in OE media (OE) at 37 ˚C.  In this 
strategy, cells harvested were subjected to a protein miniprep (Section 2.25) and purified 
SodC-t protein was analyzed by SDS PAGE. The Coomassie-stained gel has strongly 
staining bands present in the purified samples at the predicted molecular mass of SodC-t, 
16.2 kDa (Figure 3.45, at arrow). No Western blot was performed of this sample, so 






Figure 3.45: Purification of SodC-t from growth in OE at 37 ˚C 
Arrow at predicted molecular mass of SodC-t, 16.2 kDa 
1. Purified SodC-t 
 
SodC-t was then purified by protein miniprep from KCM-Rosetta-SodC cells grown 
in OE at 18 ˚C, and this purified SodC-t was analyzed by SDS PAGE in comparison to 
SodC-t grown at 37 ˚C from the previous paragraph (Figure 3.46). Strongly staining 
bands were present in the samples from both expression conditions, with more protein 
apparently being produced at 18 ˚C than 37 ˚C, however, this may be to unequal loading 
of protein samples. A Western blot was prepared from these samples as well (Figure 
3.47), which confirms the strongly staining bands at the arrow, just above the 15 kDa 






Figure 3.46: Purification gel of SodC-t 
in OE Broth 
 
Arrow at predicted molecular mass of 
SodC-t, 16.2 kDa 
1. Grown at 37 ˚C 
2. Grown at 18 ˚C 
 
Figure 3.47: Purification Western blot of 
SodC-t in OE Broth 
Arrow at predicted molecular mass of 
SodC-t, 16.2 kDa 
1. Grown at 37 ˚C 
2. Grown at 18 ˚C 
 
 
 SodC-t was then purified from strain KCM-Rosetta-SodC grown in LB broth 
induced with 1 mM IPTG at an OD600 of 0.6 and grown overnight at 18 ˚C post-
induction. This sample was purified as described in Section 2.23 and eluted from the 
column in 5 fractions, which were analyzed by SDS PAGE using a Coomassie-stained 
acrylamide gel. Figure 3.48 has strongly staining bands at the predicted molecular mass 
of SodC-t in all of the 5 fractions. These conditions were chosen for scaled-up production 





Figure 3.48: Purification of SodC-t from LB broth at 18 ˚C with 1 mM IPTG induction 
Arrow at predicted molecular mass of SodC-t, 16.2 kDa 
1-5: Eluted fractions of SodC-t 
 
SECTION 3.2 ELISA RESULTS 
Section 3.2a LolC-t and pIII-t ELISA 
ELISA was performed with LolC-t and biotinylated pIII-t to determine if the two 
proteins would bind to each other in their purified forms. As seen in figure 3.49, they do 
indeed bind to each other in a concentration-dependent manner.  
 




Section 3.2b Heat-killed cells and biotinylated pIII-t ELISA 
 ELISA was performed with heat-killed (HK) B. pseudomallei strain Bp82 and 
biotinylated pIII-t protein to determine if the LolC epitope that binds to pIII-t would be 
available in the HK cells. Pseudomonas aeruginosa strain PAO1 was used as a negative 
control. As seen in Figure 3.50, biotinylated pIII-t binds with higher affinity to HK Bp82 
cells than to HK PAO1 cells, although it is seen to bind to the HK PAO1 cells as well. 
 
 







Chapter 4: Discussion 
 
SECTION 4.1 PROJECT AIMS RECAP 
 The aims of this project were to generate highly purified surface located and 
immunogenic target proteins FliC, PilA, FimA, and LolC from B. pseudomallei and 
BopA and SodC from B. mallei. These protein targets will be used to generate high 
affinity diagnostic reagents including aptamers and antibodies that will be used in a 
diagnostic assay for melioidosis and glanders. In addition, the protein pIII was cloned, 
expressed, and purified as a diagnostic reagent to detect LolC protein.  
 
SECTION 4.2 GENERAL DISCUSSION 
 There is an intuitive and pervasive assumption that surface-expressed proteins are 
most likely to evoke an antibody response in the host, due to their accessibility to the 
immune system. Many bacterial proteins that have been shown to be protective against 
disease have signal sequences that would locate them to the outside of the cell membrane 
(Davies et al. 2005). Because of this, proteins from B. pseudomallei and B. mallei that are 
expected to be extracellular were mainly chosen for this study, including FliC, PilA, and 
FimA. Other proteins in this study included those that have already been shown to be 




It has been hypothesized that high affinity reagents such as aptamers and antibodies 
that can bind to these purified outer-membrane associated proteins could also be used to 
detect them on the surface of the bacteria, and thus would be able to capture and detect 
whole cell organisms. This work has identified one such detection reagent, pIII protein 
from the phage M13K07, which may be able to specifically detect LolC protein. The 
development of other detection reagents is yet incomplete and ongoing.  
 
SECTION 4.3 DISCUSSION OF FLIC  
 In this study, two recombinant forms of FliC were expressed and purified. One of 
these truncated proteins, FliCR-t, has been shown to be highly pure with no identified 
contaminants. The other truncated FliC, FliC-t, has not been extensively purified as of 
yet.  
 FliC remains an excellent diagnostic target. It is externally expressed on B. 
pseudomallei with many copies present in each bacterial flagellum. FliC has also been 
identified as a protein that is highly immunogenic during melioidosis infection (Felgner 
et al. 2009), confirming that it is accessible to the immune system during infection. 
Because B. mallei is non-flagellated, reagents that recognize FliC would be ideal in the 
differentiation between melioidosis and glanders infections. While this consideration is 
not integral to diagnosis in areas where melioidosis is endemic due to the low incidence 
of human glanders, it could be vital in the identification of a biological terrorism threat. 




(Suppiah et al. 2010) Currently RNA aptamers are being selected against FliCR-t. 
FliC is also a potential vaccine candidate. It has been shown that a plasmid DNA 
vaccine encoding the fliC gene is protective against melioidosis (Chen et al. 2006). This 
plasmid vaccine expressed the FliC protein in vivo, suggesting that the FliC protein itself 
could be protective without the addition of O-polysaccharide (Brett and Woods 1996). In 
addition, flagellins from other bacterial species, such as closely related Pseudomonas 
aeruginosa, have been shown to be protective against bacterial challenge (Campodonico 
et al. 2010). 
Future work with FliC-t needs to begin with size exclusion chromatography 
purification on the FPLC to remove any contaminating protein from the E. coli host 
strain. After this is done, it should be used in the generation of high-affinity aptamers, 
fragment antibodies (fABs), and commercially obtained mouse monoclonal antibodies.  
Future work on FliCR-t includes the continuation of aptamer selections, as well as the 
beginning of fAB selections and commercial production of mouse monoclonal 
antibodies. These reagents would then be used in a novel Luminex assay for melioidosis 
as well as in diagnostic assays to suit the developing world, including rapid 
immunofluorescence (Wuthiekanun et al. 2002) and latex agglutination (Amornchai et al. 
2007).  
 
SECTION 4.4 DISCUSSION OF PILA-T AND FIMA-T  




cloned, expressed, and purified.  This protein, PilA-t, is incredibly pure with no identified 
contaminants. A truncated form of FimA from B. Pseudomallei was also expressed and 
purified. This protein, FimA-t, still contains some high molecular mass contaminating 
proteins. 
 PilA is an excellent diagnostic target. It has been demonstrated that highly 
immunogenic PilA expressed during experimental glanders infection, and that PilA elicits 
an IgG immune response in the host (Fernandes et al. 2007). Both PilA and FimA also 
appear to be up-regulated during infection in response to taurine found in animal cells 
(Nandi et al. 2010). PilA, although highly immunogenic, has been demonstrated to not be 
protective against experimental glanders. Currently, PilA-t is being used for the selection 
of diagnostic reagents including aptamers and fragment antibodies (fABs).  
Future work with PilA-t would include using it as a target to obtain highly sensitive 
and selective diagnostic reagents. This includes continuing aptamer and fAB selections, 
as well as using PilA-t in the generation of commercially produced mouse monoclonal 
antibodies. It has already been shown that immunization with PilA leads to a high 
production of IgG antibodies, and it is therefore likely that high affinity antibodies would 
be obtained from the commercial mouse route.  
Future work for FimA-t has to begin with better purification methods to remove the 
high molecular mass contaminants found in the current preparation. When suitably pure 
protein has been achieved, it can also be used for the generation of diagnostic reagents 





SECTION 4.5 DISCUSSION OF LOLC-T AND PIII-T  
 In this study a recombinant truncated form of LolC from B. pseudomallei was 
expressed and purified. This protein, LolC-t, is highly purified with no identified 
contaminants. A second form of LolC-t has also been seen as a stably truncated species 
on Coomassie-stained acrylamide gel. In addition, a truncated form of the pIII gene from 
phage M13K07 was cloned, expressed, and purified to be used as a detection agent for 
LolC-t. This protein, pIII-t, is highly purified. Assays using pIII-t as a detection reagent 
for LolC-t and heat-killed B. pseudomallei Bp82 cells demonstrated it to bind with some 
specificity to both samples, but pIII also bound to the P. aeruginosa cells used as a 
negative control.  
The cellular location of LolC remains unclear. It is reported to be located in the 
periplasmic space between the inner and outer membranes of the bacteria, and have no 
surface-expressed domains (reviewed in Narita 2011), but its role as a protective antigen 
in melioidosis and glanders infections calls this into question. Because the only assay 
performed in this study was against heat-killed cells that had been broken open, no 
determination can be made about the location of this protein. However, it is apparent that 
the levels of LolC expression in B. pseudomallei are high enough to detect by interaction 
with pIII-t in vitro.  
Future work with these proteins will be necessary to characterize the nature of the 




live B. pseudomallei, B. mallei, and B. thailandensis. If it is binding with high affinity to 
live cells, it could be used as a capture agent on a Luminex assay to detect Burkholderia 
species from infected samples.  
Additional work should also be done on the second LolC-t band as seen in Figures 
3.38 and 3.39. This second band represents a stable degraded form of LolC-t that could 
be selected, used for vaccination studies, and possibly patented. To do this, the sample 
would have to be FPLC purified and fractions corresponding to the smaller band would 
be collected. This purified protein could be directly used for vaccination studies, but 
ideally it would be used to determine where the protein is being cleaved in order to 
reliably express this truncated protein as a single species. To do this, mass spectrometry 
would be performed on the purified sample to obtain the size of the peptide. This would 
be compared to the size of the LolC-t protein, 26.3 kDa. Because the polyhistidine tag on 
the N-terminus of the protein, we know that the degradation is occurring at the C-
terminal end of the protein. The number of additional amino acid residues that would 
need to be removed from the construct could then be calculated based on the difference 
between the molecular mass of the current construct and the molecular mass of the 
degraded sample. Then the further truncated LolC-t2 construct could be designed from 
this data, cloned, expressed, and purified, and this purified protein could be used in 
vaccine trials. If this LolC-t2 is protective, it would also narrow down the protective 
epitope of the LolC.  




determine if it is protective in non-human primates (Nelson et al. 2011).  
 
SECTION 4.6 DISCUSSION OF BOPA-T 
 In this study, BopA-t was expressed and purified in a different way than 
previously published (Whitlock et al. 2010). This resulted in a different pattern of the 
purified protein, including a full-length sample that had not been present in the previous 
preparation. This sample has been tested in mice and was shown to not be protective 
(data not shown), whereas the previous preparation of BopA-t was highly protective. This 
may be due to aggregates that formed in the previous preparation that are not present in 
the current preparation as described here. Future work with this preparation of BopA-t 
could include a second vaccine trial, perhaps with a different adjuvant, to attempt to 
recreate the protection as seen in Dr. Qazi’s preparation of the material. Additionally, 
further work should be done to optimize the expression and purification schema of 
BopA-t in order to prevent the degradation of the protein and provide a homogenous 
species of BopA-t that is easily reproducible. 
 
SECTION 4.7 FINAL SUMMARY 
 This study resulted in the production of several highly purified truncated protein 
targets from B. pseudomallei and B. mallei, FliC, PilA, FimA, LolC, and BopA, as well 
as the potential diagnostic reagent protein pIII from filamentous phage M13K07. 




and monoclonal antibodies, against protein targets produced in this study is ongoing. 
When these reagents become available they could be used to develop a highly specific 






Appendix: Mass Spectrometry Data 
 
 +Q3: 1.085 to 1.752 min from Sample 24 (KM022712a) of Feb2012.wiff (Turbo Spray) Max. 1.6e6 cps.
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Mass reconstruction of +Q3: 1.085 to 1.752 min from Sample 24 (KM022712a) of Feb2012.wiff (Turbo Spray) Max. 1.6e7 cps.
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 +Q3: 1.585 to 2.920 min from Sample 25 (KM022712b) of Feb2012.wiff (Turbo Spray) Max. 5.9e5 cps.
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Mass reconstruction of +Q3: 1.585 to 2.920 min from Sample 25 (KM022712b) of Feb2012.wiff (Turbo Spray) Max. 8.1e5 cps.
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 +Q3: 1.335 to 2.503 min from Sample 26 (KM022712c) of Feb2012.wiff (Turbo Spray) Max. 8.1e5 cps.
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Mass reconstruction of +Q3: 1.335 to 2.503 min from Sample 26 (KM022712c) of Feb2012.wiff (Turbo Spray) Max. 3.9e6 cps.
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 +Q3: 1.085 to 2.086 min from Sample 27 (KM022712d) of Feb2012.wiff (Turbo Spray) Max. 8.4e5 cps.
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Mass reconstruction of +Q3: 1.085 to 2.086 min from Sample 27 (KM022712d) of Feb2012.wiff (Turbo Spray) Max. 5.8e6 cps.
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